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Abstract 
Erythropoietin-producing hepatocellular receptor B4 (EphB4), a receptor tyrosine kinase 
within the Eph family, has been increasingly associated with development of human 
malignancies. However, the role of EphB4 depicted in various cancers seems divergent 
which is believed to be highly dependent on the tissue type and cell context. Previous 
studies in different tumour cohorts have suggested a positive correlation between EphB4 
expression and malignant potential in human endometrial cancer; yet its biological 
significance in endometrial tumorigenesis has not been well characterised. The aim of this 
study was to interrogate the role of EphB4 in the regulation of endometrial cancer cell 
survival and migration in vitro, and further elucidate the underlying mechanisms that 
contribute to tumour progression. 
First, we screened the expression of EPHB4 and EFNB2 transcripts across a diverse 
collection of human endometrial specimens by quantitative real-time RT-PCR. In 
agreement with previous reports, our results showed upregulation of EPHB4 and EFNB2 
expression in human endometrial adenocarcinomas in comparison to little expression in 
normal human endometrium. Then, we examined the expression of EPHB4 and EFNB2 in 
several human endometrial epithelial cell lines. Real-time RT-PCR and immunoblotting 
results demonstrated that EPHB4 and EFNB2 were commonly coexpressed in the four 
endometrial cell lines we analysed, with the strongest EphB4 protein expression detected 
in Ishikawa and HEC-1B endometrial cancer cell lines. Additionally, we observed 
differential expression of EPHB4 and EFNB2 in three-dimensional (3D) multicellular 
spheroids (MCSs) versus traditional two-dimensional (2D) cell monolayers.  
To further characterise the biological function of EphB4 in endometrial cancer cell 
progression, we knocked down EphB4 protein expression in Ishikawa and HEC-1B cell 
lines by transduction with two independent lentiviral shRNAs targeting different exons of 
EPHB4, and further assessed the effects of EphB4 downregulation on cell survival and 
motility. We found that EphB4 knockdown in Ishikawa and HEC-1B cells resulted in 
attenuated cell growth in both 2D monolayers and 3D MCSs, concurrent with impaired 
colony formation and cell migration. Conversely, overexpression of full-length EPHB4 in 
HEC-1B cells facilitated a more aggressive phenotype characterised with augmented cell 
growth, clonogenicity and migration. In addition, preliminary evidence in our study 
suggests that some focal adhesion signalling components, such as FAK, paxillin and Src, 
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are possibly involved downstream of EphB4 in the regulation of endometrial cancer cell 
survival and motility, although we observed distinctive modulation pattern in 2D versus 3D 
cell models as well as in cell lines with differential Ephs-ephrins expression profile. 
Intriguingly, despite the substantial protein levels of EphB4 in the examined endometrial 
cancer cell lines, minimal tyrosine phosphorylation was detected. This data suggests that 
endogenous EphB4 receptors in these cell lines are not constitutively activated by the 
coexpressed ephrin-B2 ligands. Our results however further demonstrated that EphB4 
receptor kinase in Ishikawa cells remained ligand-responsive since the tyrosine 
phosphorylation level of EphB4 markedly increased following stimulation with a chimeric 
ephrin-B2/Fc ligand. Activation of EphB4 kinase activity by the ligand stimulation led to 
decreased cell viability in both 2D monolayers and 3D MCSs, suggesting that ephrin-B2 
ligand-induced EphB4 kinase signalling is anti-proliferative. Moreover, treatment with a 
potent EphB4 kinase inhibitor NVP-BHG712 alone showed different effects on Ishikawa 
cell growth in 2D versus 3D cultures, with a small growth promoting effect in 2D but a 
notable proliferative effect in 3D. Furthermore, pre-treated the cells with NVP-BHG712 for 
1 hour and then followed with chimeric ephrin-B2/Fc ligand stimulation was observed to 
partially block the growth inhibitory effect of ephrin-B2-induced EphB4 kinase activity in 3D 
cultures but not seen in 2D cultures. Hence, we hypothesize that NVP-BHG712 might 
impact the signalling activity of other Eph receptor kinases in addition to the EphB4 
receptor contributing to the overall cellular response. Indeed, we have identified that 
multiple Eph receptor transcripts including EPHA3, EPHA4, EPHB1, EPHB2 and EPHB3 
are coexpressed with EPHB4 and EFNB2 in the three endometrial cancer cell lines but 
with differential expression profiles. Taken together, these data suggest that aberrant 
expression of the EphB4 receptor and ephrin-B2 ligand is likely present in endometrial 
cancer cells, such that overexpression of EphB4 leading to disruption of anti-oncogenic 
ephrinB2/EphB4 signalling. 
In summary, it is suggested that overexpression of the EphB4 receptor lacking kinase 
activation with the ephrin-B2 ligand is likely responsible for the malignant potential in 
endometrial cancer cells. The ligand-independent EphB4 signalling has been 
demonstrated to play an oncogenic role in favouring cancer cell survival and migration. On 
the contrary, ligand-dependent EphB4 kinase activity elicits a tumour-suppressing 
response in preventing endometrial cancer cell growth. The dual role of EphB4 in 
controlling the growth and migration of endometrial cancer cells is believed to act through 
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multiple mechanisms, such as modulation of focal adhesion complexes and crosstalk with 
other Eph family members to form different signalling complexes, although further 
investigations are warranted. Importantly, this study has revealed the complexities of the 
EphB4 biology in endometrial cancer cells and highlighted that studying the 
comprehensive EphB4 biology in 3D tumour cell environment can unravel novel findings 
that are not replicated in their 2D counterparts. Above all, our results also indicate that 
restoring the anti-oncogenic EphB4 kinase signalling and/or blocking the oncogenic 
kinase-independent activity of EphB4 receptor may provide a possible therapeutic strategy 
for endometrial cancer. 
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Chapter 1    General Introduction 
Endometrial cancer remains the most common gynaecological malignancy in the Western 
world. Although most of the patients diagnosed with localized disease are highly curable 
through the primary surgery of total hysterectomy and bilateral salpingo oophorectomy, for 
those who would like to reserve their fertility or those who are medically unfit, this is not an 
optimal option. Moreover, for patients with advanced or recurrent disease, morbidity and 
mortality are still at rather high levels (Murali et al., 2014, Amant et al., 2005). Therefore, 
there is an urgent need for better clinical tools that are able to circumvent unnecessary 
surgical interventions to improve current surveillance for patients with endometrial cancer; 
also to identify and treat earlier in those patients with more aggressive subtypes of 
endometrial cancer. Expanding our knowledge of the molecular and cellular pathogenesis 
during the development and progression of endometrial cancer will provide valuable 
information to improve diagnosis and treatment of this disease. A family of proteins named 
the Eph (erythropoietin-producing hepatocellular) receptors, has been highlighted in recent 
publications representing a group of promising biomarkers that is involved in the 
development of many cancer types (Pasquale, 2010, Lisle et al., 2013, Janes et al., 2008, 
Boyd et al., 2014). In contrast to other cancers, little is known about the expression, 
regulation and functional roles of the Eph receptors in the context of endometrial cancer. In 
this thesis work, we focused on the EphB4 receptor that has been extensively studied but 
shows contradicting roles in different cancers (Boyd et al., 2014), and aimed to decipher its 
role in endometrial tumorigenesis. This chapter provides a general overview of the relevant 
background information regarding endometrial cancer and the Eph family of receptors. 
1.1 Normal endometrium 
The uterus is a hollow pear-shaped organ of the female reproductive system. It is located 
in the pelvis between the bladder and the rectum. The bulk of the uterus is a layer of 
smooth muscle tissue called the myometrium. The inner lining of the uterus is a mucous 
membrane called the endometrium (NCI, 2010) (Figure 1.1).  
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Figure 1.1 Schematics of the internal female reproductive organs 
This diagram shows the ovaries, fallopian tubes, and different parts of the uterus which 
include the cervix (neck), corpus (body), fundus (top), myometrium (outer layer) and 
endometrium (inner layer). Adapted from (National Cancer Institute, 2010). 
 
The human endometrium is a highly dynamic tissue that varies in a cyclic manner 
throughout a woman’s reproductive life. Endometrial homeostasis is finely controlled by 
the hormonal balance. The ovarian steroid hormones oestrogen and progesterone play a 
prominent role in regulating the histological appearance and physiology of the 
endometrium during each menstrual cycle. Normally, oestrogen (in the form of oestradiol) 
drives proliferation of the endometrium, whereas progesterone offsets the oestrogenic 
proliferation and prepares the endometrium for embryo implantation (Lessey, 2010). The 
endometrium consists of three distinct layers, the stratum compactum, the stratum 
spongiosum, and the stratum basale epidermidis. The stratum compactum is the compact 
luminal layer covering the uterine cavity which contains the lining surface epithelium and 
the necks of the endometrial glands. The stratum spongiosum is the loose middle layer 
embedded with main portions of the endometrial glands. The stratum basale epidermidis is 
the basal layer lying directly against the myometrium which contains the bases of the 
endometrial glands. The top two functional layers undergo extensive changes during the 
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menstrual cycle, whereas the bottom layer remains relatively unaltered during the 
menstrual cycle (Ludwig and Spornitz, 1991, Harrison, 2014).  
Menopause occurs when the ovaries no longer produce the hormones oestrogen and 
progesterone that leads to the permanent cessation of ovulation and menstruation in a 
woman’s life. Most women reach menopause naturally between 45 and 55 years of age. 
However, sometimes it occurs earlier than expected caused by cancer treatment, surgery 
or unknown causes (Jean Hailes, 2014). As a result, the endometrium becomes thinner 
and inactive (NCGC, 2010).  
The endometrium is composed of mesodermal-derived glandular and luminal epithelial 
cells and the surrounding stromal cells (Ludwig and Spornitz, 1991, Classen-Linke et al., 
1997, Adissu et al., 2007) (Figure 1.2). Human endometrial stromal cells have been 
demonstrated to regulate the growth and differentiation of endometrial epithelial cells 
through paracrine interactions (Cooke et al., 1997, Arnold et al., 2001, Arnold et al., 2002). 
In addition, a population of stem/progenitor cells which reside in the basalis of endometrial 
glandular epithelium and the underlying stromal compartments might be responsible for 
the remarkable regenerative capacity of human endometrium (Gargett et al., 2007). 
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Figure 1.2 Organisation of the epithelia in the human endometrium 
In the human endometrium, the luminal surface epithelium is formed by a single layer of 
columnar cells which are composed of a mixture of ciliated cells and microvilliated 
secretory cells. Invaginations from the luminal epithelium form the tubular endometrial 
glands. Both the luminal and glandular epithelial cells are anchored to a basement 
membrane (BM) and supported by the surrounding tissue stroma. Magnified cells (to the 
right) exhibit features of the basal-apical polarity axis. Cell-cell tight junctions (TJs) and 
desmosomes are present along the lateral surface of adjacent epithelial cells. Modified 
from (Adissu et al., 2007). 
 
1.2 Endometrial hyperplasia 
Endometrial hyperplasia is an overgrowth of both endometrial glands and stroma, and is 
characterised by a proliferative glandular pattern with or without different degrees of 
cytologic atypia (Mutter, 2000). Compared with normal proliferative endometrium, 
endometrial hyperplasia has an increase in the endometrial gland to stroma ratio (Owings 
and Quick, 2014). It is usually resulted from an imbalance between oestrogen and 
progesterone in the endometrium - continuous and prolonged exposure to unopposed 
oestrogen stimulation while lacking the counteracting effects of progesterone (Montgomery 
et al., 2004, Kiechle et al., 2000). 
Chapter 1: General Introduction  
 
5 
 
Currently, two diagnostic schemas are in use: the four-class 1994 World Health 
Organization (WHO) hyperplasia classification system (Bonfiglio et al., 1994), and more 
recently, the two-class endometrial intraepithelial neoplasia (EIN) sequence classification 
system as defined by the International Endometrial Collaborative Group (Baak and Mutter, 
2005). The 1994 WHO criteria classifies endometrial hyperplasia into four categories 
(simple hyperplasia, complex hyperplasia, simple hyperplasia with atypia, and complex 
hyperplasia with atypia) based on histologic assessment of architectural complexity and 
nuclear atypia, which is largely variable and subjective. Yet, the EIN criteria is based on 
objective correlation of computer-assisted morphometric data with molecular and clinical 
progression annotations and divides endometrial hyperplasia into benign hyperplasia and 
EIN, which has been proved to be more accurate and reliable (Owings and Quick, 2014). 
Comparison of these two classification systems, with correlation of the clinical outcome 
reveals a degree of overlapping. The majority of EIN lesions are actually equivalent to 
most of the WHO atypical endometrial hyperplasia category (Hecht et al., 2005).  
In the last two decades, significant advances have been made in defining endometrial 
precancers (Abushahin et al., 2013). EIN has been widely accepted as a precancer of 
endometrioid endometrial adenocarcinoma (Mutter, 2000, Zaino, 2000). On the other hand, 
recent studies have proposed that endometrial glandular dysplasia (EmGD), a non-classic 
type of EIN lesion, is a precancer of serous and clear cell endometrial carcinomas (Liang 
et al., 2004, Yi and Zheng, 2008, Zheng et al., 2011). Treatment of endometrial 
hyperplasia depends on the patient's age, fertility desire and the type of hyperplasia. 
Progestin therapy is the most commonly used medical treatment in current management 
practices. However, clinical trials of hormonal therapies for atypical endometrial 
hyperplasia or EIN have not yet established a standard regimen. In some of these patients, 
hysterectomy may be performed as a definitive surgical treatment (Gültekin et al., 2009, 
Jadoul and Donnez, 2003, Trimble et al., 2012). 
1.3 Endometrial cancer 
1.3.1 Incidence of endometrial cancer 
Endometrial cancer usually starts in the endometrium and accounts for most cases of 
uterine cancer. It is the most commonly diagnosed gynaecological cancer in developed 
countries. In Australia, endometrial cancer is the sixth most common cancer in women, 
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with 2,238 new cases diagnosed and 378 deaths from the disease in 2011 (AIHW, 2015). 
The majority cases of endometrial cancer are diagnosed in postmenopausal women over 
60 years of age. However, its incidence among premenopausal women is rising, 
predominantly due to an increasing prevalence of obesity which is considered as a major 
risk factor for endometrial cancer in this age group (Dougan et al., 2015).  
Despite the prevalence of endometrial cancer, little is known of its precise aetiology. 
Approximately 90% of cases are considered sporadic; and the remaining 10% are 
hereditary, typically in women with familial Lynch syndrome (Okuda et al., 2010). Other 
than the inherent factors, studies have identified several risk factors for endometrial cancer 
including obesity, diabetes mellitus, hypertension, oestrogen-only hormone replacement 
therapy, chronic anovulation, and various reproductive factors such as early age at 
menarche, late age at menopause and nulliparity. All of these factors seem to possibly 
contribute to a milieu of excessive levels of unopposed oestrogen in the endometrium 
which stimulates the proliferation of endometrial epithelial cells (Purdie and Green, 2001, 
Amant et al., 2005). Nonetheless, obesity remains a strong risk factor for endometrial 
cancer even when circulating concentrations of oestrogen are normal. One possible 
explanation is that increased insulin/insulin-like growth factor (IGF) signalling can induce 
transcriptional activity of oestrogen receptor through oestrogen-independent pathways 
(Khandekar et al., 2011, Amant et al., 2005). 
1.3.2 Types of endometrial cancer 
Endometrial carcinomas can be classified based on the appearance of cancer cells under 
the microscope and described by their histologic type and tumour grade. The histologic 
type refers to the outlook of cancer cells and how they are arranged. The grade refers to 
the extent of similarity of cancer cells to normal cells forming the endometrial glands. 
Grade 1 tumours have more than 95% of the cancerous tissue forming glands. Grade 2 
tumours have between 50% and 94% of the cancerous tissue forming glands. Grade 3  
tumours (high-grade) have less than 50% of the cancerous tissue forming glands and they 
are more aggressive relative to low-grade tumours (Grades 1 and 2) (ACS, 2015). 
Currently, the most widely used histopathological classification of endometrial cancer is 
the so-called dualistic model proposed by Bokhman. According to this classification 
system, endometrial carcinomas can be categorised into two distinct types, namely type I 
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and type II cancers (Bokhman, 1983). WHO also classifies endometrial cancers into 
several histological types, with the most common subtypes being endometrioid carcinoma, 
serous carcinoma, clear-cell carcinoma, and carcinosarcoma (Tavassoli et al., 2003). Type 
I cancers are oestrogen-dependent and have endometrioid histology, which represent at 
least 80% of all the cases. Some rare forms including secretory carcinoma, ciliated 
carcinoma, and mucinous carcinoma are also classified into this type (Plataniotis and 
Castiglione, 2010). Type I cancers are usually well or moderately differentiated tumours 
displaying hormone-receptor positivity, and the pathogenesis is commonly associated with 
unopposed oestrogen stimulation and obesity. In general, this type of endometrial cancer 
occurs in women at a comparatively younger age (under 50 years of age) with favourable 
clinical outcomes. In contrast, type II cancers are much less common in endometrial 
carcinoma, making up only 10 – 15% of diagnosed cases. Cancers in this category include 
serous carcinoma, clear-cell carcinoma and poorly differentiated carcinoma, which are 
believed to arise in atrophic endometrium and are unlikely to be related with oestrogen or 
obesity. Type II cancers are usually more aggressive and have a relatively poor prognosis 
in comparison to type I cancers (Horn et al., 2007). Approximately 80% of endometrial 
cancer-associated deaths are resulted from type II cancers (Ueda et al., 2008). Molecular 
data also suggest that different mechanisms of establishment and progression exist 
between the two subtypes of endometrial cancer. For example, type I endometrioid 
carcinomas are frequently associated with mutations in genes such as PTEN, KRAS, 
CTNNB1, and PIK3CA, and microsatellite instability (MSI), whereas type II cancers often 
show HER2 amplification and mutations of TP53 and CDH1 (Murali et al., 2014) (Table 
1.1).  
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Table 1.1 Clinicopathological features of type I and type II endometrial cancers 
 Type I Type II 
Menopause status Pre- and peri- menopausal Postmenopausal 
Oestrogen-related Yes No 
ER or PR Present Absent 
Obesity Yes No 
Background of endometrium Hyperplastic Atrophic 
Precancer EIN (classic) EmGD  
Histology Endometrioid  Serous,  clear-cell, and 
poorly- differentiated 
endometrioid  
Tumor grade Low (Grades 1 and 2) High (Grade 3) 
Stage at diagnosis Early (FIGO stage I, II) Advanced (FIGO stage III, IV) 
Clinical behaviour Indolent Aggressive 
Prognosis Favourable Unfavourable 
ER: oestrogen receptor; PR: progesterone receptor; EIN: endometrial intraepithelial 
neoplasia; EmGD: endometrial glandular dysplasia; FIGO: International Federation of 
Gynaecology and Obstetrics. Modified from (Murali et al., 2014, Zheng et al., 2011). 
 
However, there is substantial heterogeneity in biological, pathological and molecular 
features within each subtype of endometrial cancer from above classification systems. 
Thus, interest has been raised most recently in developing integrated classification that 
incorporates genomic and histopathological features to define biologically and clinically 
relevant subsets of endometrial cancer. Based on integrated genomic data, Murali and 
colleagues proposed that endometrial carcinomas could be grouped into four classes: (1) 
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POLE ultramutated, (2) MSI hypermutated, (3) copy-number low, and (4) copy-number 
high (Murali et al., 2014) (Table 1.2). Such conceptual classification might facilitate 
development of more appropriately tailored treatments for this disease. 
 
Table 1.2 Characteristics of four genomic classes of endometrioid and serous 
carcinomas 
 
Adapted from (Murali et al., 2014). 
 
1.3.3 Current management of endometrial cancer 
Patients with endometrial cancer commonly present with postmenopausal vaginal bleeding. 
As a result, most patients (around 75%) are diagnosed at an early stage (FIGO stages I 
and II) when the tumor is mostly confined to the uterus, and the prognosis is generally 
good as indicated by the overall 5-year survival rate of 74 – 91% (Murali et al., 2014). 
However, the recurrence rate for early stage endometrial cancer within three years after 
primary treatment ranges from 3 to 17% (Nicolaije et al., 2013). In addition, the overall 5-
year survival rate for FIGO stage III and IV drastically drops to 57 – 66% and 20 – 26%, 
respectively (Murali et al., 2014). Thus, development of more accurate diagnosis and 
improved treatment is of paramount importance to the therapeutics of this disease.  
The current diagnosis is still based on conventional pathological indicators, such as clinical 
stage, tumor differentiation, invasion depth and vascular invasion. Several useful 
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histological biomarkers for endometrial cancer have been identified, including steroid 
receptor status (ER/PR), p53, PTEN, PI3K/Akt/mTOR, Ras/MAPK/ERK, MSI, β-catenin, 
VEGF and DNA aneuploidy. Serum markers include carbohydrate antigen 125 (CA125), 
carbohydrate antigen 15-3 (CA15-3), chitinase 3-like 1 protein (YKL-40), VEGF and 
human epididymal secretory protein E4 (HE-4) (Gadducci et al., 2011, Banno et al., 2013, 
Chaudhry and Asselin, 2009, Tomica et al., 2014, Stoian et al., 2011). Recent studies also 
suggest that epigenetic mutations involving such as microRNAs may serve as new 
candidate biomarkers for endometrial cancer (Banno et al., 2013). Though the emerging 
biomarkers lead to the possibility of new methods of diagnosis and treatment planning, 
very few of the above molecular markers is implemented in routine clinical practice since 
only a minority of them is reproducible (Amant et al., 2005), and aneuploidy is hard to 
implement. 
Standard treatment options for endometrial cancer include surgery, adjuvant 
chemotherapy, radiotherapy and hormone therapy. A thorough lymphatic dissection is 
usually recommended for patients with papillary serous and clear cell carcinomas given 
that these histologic types of endometrial cancer have a higher incidence of metastatic 
disease and the pattern of spread resembles that of ovarian cancer, which is different from 
endometrioid carcinoma. Currently, there is no proof that adjuvant hormone therapy or 
chemotherapy results in a better outcome in papillary serous and clear cell carcinomas 
(Amant et al., 2005). However, two on-going studies, the EORTC 55991 and the PORTEC 
3 randomised trials that have included patients with papillary serous and clear cell 
endometrial carcinomas are expected to assess the role of adjuvant chemotherapy and 
radiotherapy for these more aggressive and less understood subtypes (Colombo et al., 
2013). Moreover, progression has been made during the last two decades in diagnostic 
imaging, radiation delivery systems, and systemic therapies to provide more valuable data 
for optimising endometrial cancer treatment. Meanwhile, the availability of novel hormonal 
and biological regimes also offers new opportunities for therapy (Mehasseb and Latimer, 
2012, Zhang and Wang, 2010). Nonetheless, controversies remain in the treatment of 
early stage endometrial carcinoma including fertility-sparing options for younger patients 
and the options of hormone replacement therapy (Press and Gotlieb, 2012, Burke et al., 
2014). Many challenges remain in the current management of endometrial cancer, such as 
overcoming drug resistance in chemo- and hormonal therapy (Chaudhry and Asselin, 
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2009), delivery of optimal therapy for patients with advanced disease, making more 
accurate prediction of individual risks of cancer recurrence after surgery, and development 
of novel targeted therapies (Burke et al., 2014).  
Overall, identification and characterisation of additional biomarkers might help with a better 
understanding of this heterogeneous neoplastic disease. Establishment of effective 
biomarkers may indicate new avenues for earlier detection and more accurate prediction 
of clinical outcomes, and is likely to contribute to future personalized therapy for 
endometrial cancer.  
1.4 Eph receptors and ephrin ligands 
1.4.1 The Eph family of receptors 
The Eph family of receptors constitutes the largest subfamily of receptor tyrosine kinases 
(RTKs), and is designated as “Eph” because the first described receptor was cloned from 
a human erythropoietin-producing-hepatocellular carcinoma cell line (Hirai et al., 1987). 
Fourteen Eph receptors have been identified in the human genome, which interact with 
their ephrin (derived from Eph family receptor interacting proteins) ligands. The Eph 
receptors are divided into two distinct classes, A and B, based on sequence homology and 
their binding affinities to A- or B- class ephrin ligands (Pasquale, 1997, Committee, 1997). 
Both of Ephs and ephrins are membrane-bound proteins. Generally, the EphA receptors 
(EphA1 to EphA8, and EphA10) interact with the glycophosphatidylinositol (GPI)-linked 
ephrin-A ligands (ephrin-A1 to ephrin-A6); while the EphB receptors (EphB1 to EphB4, and 
EphB6) interact with the transmembrane ephrin-B ligands (ephrin-B1 to ephrin-B3). 
However, it has been found that the Eph-ephrin interactions are promiscuous within each 
class, with some Ephs being able to bind to ligands of the other class. For example, 
EphA4 can bind several ephrin-B ligands and the EphB2 receptor can interact with ephrin-
A5 in addition to all three ephrin-B ligands (Himanen et al., 2004, Kullander and Klein, 
2002). One exception is that EphB4 preferably binds ephrin-B2 (Blits-Huizinga et al., 2004). 
1.4.2 Structure of Eph receptors and ephrin ligands 
The Eph receptors are type I transmembrane proteins that share a common protein 
structure vital to their biological functions (Hubbard, 1999, Ullrich and Schlessinger, 1990). 
Their extracellular domain contains a 180-amino acid N-terminal globular ephrin ligand 
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binding domain, and a cysteine rich region containing an epidermal growth factor (EGF)-
like motif which is also involved in ligand binding. The ectodomain portion also includes 
two fibronectin type III repeats that are thought to stabilize the dimerisation of Eph 
receptors, which is required for activation of intracellular signaling cascades (Himanen and 
Nikolov, 2003, Pasquale, 2005). This is separated by a single-pass transmembrane 
segment from the intracellular, cytoplasmic portion of the receptor. The intracellular 
domain is comprised of a juxtamembrane region, a tyrosine kinase domain with several 
conserved tyrosine residues, through which intracellular signaling cascades are activated, 
followed by a sterile alpha motif (SAM) domain, and a PDZ (post synaptic density protein 
PSD-95, Drosophila disc large tumor suppressor, and zona occludens-1 protein) binding 
domain. The latter two domains in the intracellular portion of Eph receptors are thought to 
additionally interact with cytoskeletal and other intracellular proteins (Pasquale, 2005). 
 
Similarly, the ephrin ligands also contain a globular N-terminal binding domain for receptor 
binding, which is separated from the membrane by a linker of approximately 40 amino 
acids. The ephrin-A ligands are anchored to the plasma membrane via a GPI linkage, 
while the ephrin-B ligands attach to the cell membrane through their single-pass, 
hydrophobic transmembrane domain. The ephrin-B ligands also have a PDZ domain and 
conserved intracellular tyrosine residues for signaling (Himanen and Nikolov, 2003, 
Gauthier and Robbins, 2003, Lin et al., 1999) (Figure 1.3). 
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Figure 1.3 Eph receptors and ephrin ligands protein domain structure 
Cysteine (Cys)-rich, fibronectin (FN) type III, and SAM domains; transmembrane (TM) 
regions; and tyrosine phosphorylation sites (Y) are indicated. EphA receptors typically bind 
ephrin-A (GPI-anchored) ligands, and EphB receptors bind ephrin-Bs (arrows). There is 
limited crosstalk between members of different classes (dashed arrows). Adapted from 
(Pitulescu and Adams, 2010). 
 
1.4.3 The Eph/ephrin signalling  
Eph-ephrin binding requires an initial cell-to-cell contact and thereafter triggers bi-
directional signal transduction (Davis et al., 1994). The signalling pathway downstream of 
the Eph receptor is referred to as “forward signalling”, while the signalling pathway 
downstream of the ephrin ligand is referred to as “reverse signalling” (Himanen and 
Nikolov, 2003, Pasquale, 2005). Eph-ephrin interactions usually occur in trans, in which 
cases Eph receptors on the surface of one cell bind to the membrane-bound ephrin 
ligands of an opposing cell leading to the activation of Eph receptors (Davis et al., 1994). 
Of note, activation of Eph receptors depends on binding to clustered ephrin ligands which 
induces receptor cis-dimerisation and further results in the formation of a trans-
heterotetrameric complex consisting of two receptors and two ligands (Elke Stein, 1998). 
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However, cis interactions could also occur, in some cases, where the Eph receptor and 
ephrin ligand are coexpressed in the same cell (Egea and Klein, 2007). This type of 
binding does not lead to active signaling, but rather seems to impair Eph receptor 
activation (Flanagan, 2006, Kao and Kania, 2011, Arvanitis and Davy, 2008) (Figure 1.4). 
Meanwhile, it has also been reported that coexpressed Eph receptors and ephrin ligands 
are likely to be segregated in distinct membrane domains with opposing functional roles in 
the modulation of cell adhesion and repulsion (Marquardt et al., 2005). Moreover, though 
Eph forward signalling depending on the kinase activity is regarded as a canonical 
mechanism, Eph signals can also be initiated through ephrin-dependent but kinase-
independent pathways, which are believed to be transduced through the additional protein 
interaction domains in the Ephs, such as PDZ binding motif (Boyd et al., 2014). For 
example, short splice variants of the receptor EphA7 lacking the cytoplasmic kinase 
domain can convert repulsive cellular responses into adhesion (Holmberg et al., 2000). 
Alternatively, the EphB6 receptor, which is thought to be catalytically inactive due to the 
alteration of several critical residues in its kinase domain, however has been shown to 
undergo inducible tyrosine phosphorylation upon stimulation with ephrin-B1 through a 
crosstalk with EphB1 receptor (Freywald et al., 2002). 
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Figure 1.4 Schematic diagrams showing main features of bi-directional Eph/ephrin 
signalling 
(A) Interactions between A- or B- class of Eph receptors and their cognate ephrin ligands 
lead to the activation of bi-directional signals through forward (Eph-initiated) and reverse 
signalling (ephrin-initiated) into neighbouring cells. (B) Eph receptors and ephrins 
expressed in opposing cells interact in “trans” and activate bi-directional signalling, while 
Eph receptors and ephrins coexpressed in the same cell interact in “cis” which impairs 
trans-interactions. Adapted from (Arvanitis and Davy, 2008). 
 
In addition to trans- and cis- interactions, several alternative modes of modulating Eph-
ephrin signalling have been proposed (Pitulescu and Adams, 2010). Remarkably, some of 
the activities of Ephs and ephrins appear not to rely on physical receptor–ligand 
interactions. Accumulating evidence has pointed out that Eph receptors can modulate cell 
behaviour independently of ephrin binding (Lisabeth et al., 2013, Pasquale, 2010, Blits-
Huizinga et al., 2004). The EphB4 receptor has been proposed to inhibit integrin-mediated 
cell adhesion independently of its preferred ligand ephrin-B2 (Noren et al., 2009). There is 
also evidence to support that the Eph receptor tyrosine kinase domains can initiate forward 
signalling without binding to the ephrin ligand by phosphorylation of each other. For 
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instance, activation of EphA3 by ephrin-A5 in trans generates an initially small signal which 
can be further expanded laterally through Eph–Eph cis interactions (Wimmer-Kleikamp et 
al., 2004). Formation of the cis-multimers also repositions the ephrin transmembrane and 
cytoplasmic domains leading to phosphorylation of a conserved region in its cytoplasmic 
tail which initiates reverse signalling (Himanen and Nikolov, 2003). Conversely, studies 
have shown that ephrin-B2 ligand can also signal in a cell-autonomous mode in the 
absence of receptor binding (Foo et al., 2006, Bochenek et al., 2010). On the other hand, 
feedback regulatory mechanisms exist to dynamically control the size and lifespan of the 
Eph/ephrin signalling complexes. For example, termination of Eph/ephrin signalling can be 
achieved by the removal of Eph/ephrin complexes from the cell surface through the 
protease-mediated cleavage machinery (Hattori et al., 2000, Xu et al., 2009, Janes et al., 
2009). However, cleavage of Eph receptors and ephrins and release of their ectodomains 
in the extracellular milieu also raises the mind-boggling possibility that the action of these 
proteins might encompass long-range paracrine interactions in addition to short-range 
cell–cell interactions (Arvanitis and Davy, 2008). Alternatively, Eph-ephrin signaling can be 
terminated through an unusual endocytic mechanism involving the internalisation of 
Eph/ephrin complexes (Mann et al., 2003, Zimmer et al., 2003, Lauterbach and Klein, 
2006) (Figure 1.5).  
Overall, different mechanisms are seemingly to cooperate in control of many aspects of 
cellular behaviour and function, including cell proliferation, differentiation, survival, 
adhesion and migration, which contribute to considerably diverse outcomes of the 
Eph/ephrin signalling system. Crosstalk with a wide range of other signalling pathways, 
such as other cell surface receptors (EGFR, FGFR, VEGFR) signalling, Rho and integrin-
associated cytoskeletal remodelling, RAS-MAPK mitogenic signalling, and PI3K-Akt cell 
survival signalling cascades, further contributes to the complexity of Eph/ephrin signalling 
(Pitulescu and Adams, 2010, Pasquale, 2010, Nievergall et al., 2012, Batlle and Wilkinson, 
2012, Arvanitis and Davy, 2008, Perez White and Getsios, 2014). Thus, biological 
functions of Eph/ephrin signalling system are highly dependent on cellular context. 
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Figure 1.5 Schematic diagrams illustrating alternative Eph/ephrin signalling modes 
in addition to the bi-directional interactions 
(A) Eph forward signalling expands through large receptor clusters by Eph-Eph cis 
interactions. (B) Eph/ephrin signalling complex is removed from the cell surface through a 
protease-associated cleavage mechanism. (C) Eph/ephrin complex can also be 
dissociated from the plasma membrane in a forward or reverse direction through a trans-
endocytosis mechanism to terminate the Eph/ephrin interactions. Adapted from (Pitulescu 
and Adams, 2010). 
 
1.5 The paradoxical roles of Eph receptors in human cancers 
Numerous studies attest to pivotal roles for Eph receptors and their ephrin ligands in 
controlling many critical processes during malignant transformation and cancer 
progression (Janes et al., 2008, Nievergall et al., 2012, Merlos-Suarez and Batlle, 2008, 
Surawska et al., 2004, Pasquale, 2008). However, Eph signalling activities in cancer 
appear to be complex. Controversy resides in the oncogenic role of Eph receptors as both 
upregulation and downregulation of Ephs have been correlated with clinical outcomes in 
cancer (Hafner et al., 2004, Pasquale, 2010, Lisle et al., 2013, Surawska et al., 2004) 
(Table 1.3). Consistent with this dichotomy, there is good evidence that, in particular 
EphB2 and EphB4, which can act as a tumor promoter or a tumor suppressor depending 
on the type of cancer, or even both in the same type of cancer (Batlle and Wilkinson, 2012, 
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Noren and Pasquale, 2007). Despite years of extensive research with respect to the 
Eph/ephrin system, molecular basis underlying the divergent signalling activities of Eph 
receptors in human cancers remains largely unknown. 
 
Table 1.3 Examples demonstrating correlations between Eph receptor or ephrin 
ligand expression and the prognostic outcomes in various cancer types 
 
Adapted from (Lisle et al., 2013). 
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1.5.1 Tumour-suppressing effects of Eph receptors  
Decreased Eph levels in malignant cancer cell lines and tumor specimens have been 
reported. For example, EphA1 is down-regulated in advanced human skin and colorectal 
cancers (Hafner et al., 2006); and EphB6 expression in metastatic lung cancers has been 
reported to be lower than their non-metastatic counterparts (Muller-Tidow et al., 2005). 
Nevertheless, in many cancer cell lines, Eph receptors appear to be highly expressed but 
poorly activated by ephrins, as indicated by their low level of tyrosine phosphorylation. 
These results suggest that ephrin-dependent Eph forward signalling may be detrimental to 
tumor progression. 
Indeed, cancer cells appear to elude the tumor-suppressing effects of Eph forward 
signalling through a variety of mechanisms. For example, upregulation of EphA2 or EphB 
expression along with decreased or loss expression of the ephrin ligand result in very little 
Eph/ephrin signalling activity in some cancers. Besides, coexpressed Eph receptors and 
ephrins often do not interact effectively in cancer cells which might due to the engagement 
of cis-interactions that impairs the trans-signalling (Pasquale, 2010, Boyd et al., 2014), or 
by loss of E-cadherin, or negatively regulated by phosphotyrosine phosphatases to disrupt 
the ephrin-dependent Eph activation (Zantek et al., 1999, Wimmer-Kleikamp et al., 2008). 
Alternatively, Eph mutations may also contribute to impaired ephrin binding or kinase 
activity (Ruhe et al., 2007, Zogopoulos et al., 2008, Smith et al., 2004). On the other hand, 
forcing Eph receptor activation with soluble Fc fusion proteins of ephrin ligands has been 
demonstrated to inhibit proliferation, survival, migration and invasion of many types of 
cancer cells in culture as well as in vivo tumor growth. Activation of Eph receptor kinases 
by their ephrin ligands remarkably inhibits oncogenic signalling pathways, such as the 
RAS-MAPK, PI3K-Akt and Crk-Rac1 pathways, which might reflect a physiological function 
of the Eph system in maintaining epithelial homeostasis by promoting cell contact-
dependent growth inhibition and decreasing cell motility and invasiveness. Additionally, 
tumor-suppressing effects of Eph forward signalling may also be active at the tumor 
periphery by interacting with ephrins expressed in the surrounding tissues to prevent tumor 
extension and invasion. Moreover, Eph receptors may further decrease tumor 
invasiveness by promoting the formation of tight junctions in neighbouring epithelial cells 
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through the stimulation of ephrin-B reverse signalling (Noren and Pasquale, 2007, 
Pasquale, 2010). 
1.5.2 Tumour-promoting effects of Eph receptors  
Conversely, forward and/or reverse Eph-ephrin signals can enhance malignant 
transformation and tumor progression in some cases. However, ephrin-dependent Eph 
signalling might be dispensable in cancer cells. There is increasing evidence showing that 
Eph receptors are capable of signalling independently of their ephrin ligands often by 
crosstalk with other oncogenic signalling pathways to increase cancer cell malignancy. 
Moreover, ephrin-independent activities of Eph receptors may also include modulation of 
the subcellular localisation of signalling partners that are constitutively associated with an 
Eph receptor or become associated as a result of Eph phosphorylation by other kinases 
(Pasquale, 2010). For example, EphA2 has been shown to be preferentially expressed in 
the basal breast cancer cells (Zhuang et al., 2010, Huang et al., 2007), and its 
overexpression in non-transformed MCF10A mammary epithelial cells facilitates 
tumorigenicity both in vitro and in vivo by cooperating with HER2 oncogene to enhance 
RAS-MAPK signalling (Zelinski et al., 2001). Likewise, EphB4 is also widely expressed in 
human cancer cells and its increased abundance has been correlated with cancer 
progression though this is more controversial (Noren and Pasquale, 2007, Kumar et al., 
2009, Takai et al., 2001, Ferguson et al., 2014, Xia et al., 2005a, Xuqing et al., 2012, 
Ferguson et al., 2013). Activation of RhoA downstream of EphB4 has been reported to 
promote ameboid-type migration of cancer cells and destabilize epithelial adherent 
junctions in melanoma cells, even though it inhibits mesenchymal-type migration (Yang et 
al., 2006). Moreover, EphB4 expression can be induced by loss of PTEN, p53, or by 
EGF/EGFR and IGF-1/IGF1R signalling to promote the growth and migration of prostate 
cancer cells (Xia et al., 2005b). In addition, it has been well established that the Eph 
system promotes tumour angiogenesis (Pasquale, 2010, Boyd et al., 2014). 
Recent studies have revealed that complex mechanisms of regulation including genetic 
and epigenetic are parallel with the multiplicity of Eph activities in cancer cells. For 
example, chromosomal alterations and changes in mRNA stability can regulate Eph and 
ephrin expression in cancer cells. Furthermore, several Ephs and ephrins are unregulated 
in vascular cells by tumour-derived factors and hypoxia, such as TNFα, VEGF-A and HIF-
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2α (Pasquale, 2010). Further elucidating the mechanisms underlying above opposing 
effects will help to address the functional roles of the Eph system in cancer. 
1.6 Three-dimensional cell cultures are more physiologically relevant for modelling 
glandular epithelial cancers in vitro 
Three-dimensional (3D) in vitro cultures are recognised for their merits in recapitulating the 
physiological microenvironment and exhibiting high concordance with in vivo conditions. 
This class of in vitro model system has an enormous potential in increasing our 
understanding of cellular behaviour and function in tissue homeostasis and during the 
process of oncogenesis. Such 3D culture systems manifest two unique characteristics that 
address some of the limitations of two-dimensional (2D) monolayer cell culture, or whole 
animal models and human tissues. First, they are readily amenable to experimental 
manipulation and detailed microscopic and biochemical analyses. Second, they 
recapitulate certain essential structural features of native tissue organisation with good 
fidelity, such as the reciprocal interactions between tumour cells and their 
microenvironment (Debnath and Brugge, 2005, Kim, 2005, Pampaloni et al., 2007). Thus, 
3D culture systems provide a robust experimental tool for modelling biological activities of 
cancer-related genes and signalling pathways in a structurally appropriate context. In this 
regard, tumour cells cultured in 3D, as compared to cells in conventional 2D culture, 
display compelling advantages in modelling a spectrum of major in vivo-like properties, 
including differentiation, gene expression, morphology, proliferation, migration and 
invasion, response to stimuli and drug metabolism (Birgersdotter et al., 2005, Yamada and 
Cukierman, 2007, Justice et al., 2009) (Table 1.4). 
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Table 1.4 Three-dimension dependent cell behaviour and cell signalling 
 
Adapted from (Yamada and Cukierman, 2007). 
 
The primary advantage that 3D cultures have over 2D monolayer is the well-defined 
architecture, which makes it possible to directly relate structure to function and in turn 
enable theoretical analyses (Yamada and Cukierman, 2007). Loss of cell-cell adhesion 
and cell polarity is a hallmark of cancer (Wodarz and Nathke, 2007, Lee and Vasioukhin, 
2008). Consistent with this, early studies have revealed that in 3D cultures glandular 
epithelial tumour cells do not form acinus-like spheroids which are typical structures 
formed by their non-malignant counterparts. Strikingly, tumour cells developed into non-
polarised multicellular spheroids (MCSs) or clusters with limited differentiation (Debnath 
and Brugge, 2005). In addition, 3D structures are composed of heterogeneous cells in 
different states such as proliferating, quiescent, and necrotic cells, which is very similar to 
the situation within intact human tumours. The MCSs formed by tumour cells in 3D have 
shown comparable drug sensitivity patterns of tumours in vivo that are remarkably 
discriminated from the results obtained in 2D. Notably, tumour cells exhibit greater drug 
resistance to cytotoxic treatment regimes in 3D cultures and can dynamically switch 
between alternative pathways that regulate proliferation, differentiation and survival 
depending on different culture conditions (Debnath and Brugge, 2005, Kim, 2005, Zahir 
and Weaver, 2004, Birgersdotter et al., 2005, Weigelt et al., 2010). 
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1.7 Rationale, Hypothesis and Aims 
A growing body of evidence has implicated a crucial role for the EphB4 receptor kinase 
during neoplastic development and progression of various human malignancies (Noren 
and Pasquale, 2007, Boyd et al., 2014, Lisle et al., 2013). Moreover, EphB4 and its 
cognate ligand ephrin-B2 are reported to play essential roles in tumour angiogenesis 
(Noren et al., 2004, Kertesz et al., 2006). Thus, EphB4 remains an attractive target for 
potential cancer therapy. 
However, the role of EphB4 appears paradoxical in different cancers (Noren and 
Pasquale, 2007, Boyd et al., 2014). EphB4 overexpression is commonly found to correlate 
with tumour progression and poor survival in many cancer types, including breast (Wu et 
al., 2004, Kumar et al., 2006), prostate (Xia et al., 2005b, Lee et al., 2005), colorectal 
(Kumar et al., 2009, Stephenson et al., 2001), lung (Ferguson et al., 2013), oesophageal 
(Hasina et al., 2013), and ovarian cancer (Alam et al., 2008), suggesting a tumour-
promoting role for EphB4 overexpression. On the other hand, there is also evidence 
arguing for EphB4 as a tumour suppressor in some cases of breast (Berclaz et al., 2002), 
colorectal (Davalos et al., 2006, Ronsch et al., 2011, Batlle et al., 2005), and intestinal 
cancer (Dopeso et al., 2009). It is now generally recognised that EphB4 kinase signalling 
activated by its preferred ligand ephrin-B2 is tumour suppressive, whereas the tumour-
promoting function of EphB4 is predominantly mediated independent of the ligand due to 
deregulation of EphB4/ephrin-B2 signalling in cancer cells, coupled with activation of 
neoangiogenic reverse signalling in adjacent ephrin-B2-bearing endothelial cells (Noren 
and Pasquale, 2007, Boyd et al., 2014, Lisle et al., 2013). Nevertheless, ligand stimulation 
of EphB4 has been reported to promote the growth and migration of melanoma cells (Yang 
et al., 2006, Yang et al., 2010). Given the considerable complexity of EphB4/ephrin-B2 
signalling functions, determining the complex roles of EphB4 activity is highly dependent 
on the tissue type and cellular context.  
Currently published data have demonstrated prominent upregulation of EphB4 receptors in 
endometrial tumours in comparison to normal endometrium (Takai et al., 2001, Berclaz et 
al., 2003, Alam et al., 2007). Strong expression of EphB4 has also been reported in 
endometrial hyperplasia (Berclaz et al., 2003). Although these findings suggest that EphB4 
might be involved in endometrial tumour progression, the potential role of EphB4 in 
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endometrial cancer biology has not been well characterised. To our knowledge, this is the 
first study to screen the expression of EphB4 receptor and its ligand ephrin-B2 in a range 
of endometrial epithelial cell lines with a cohort of endometrial tissue specimens and 
further address its biological function in endometrial tumorigenesis. We hypothesised that 
EphB4 forward signalling plays a role in endometrial tumour progression through the 
regulation of cancer cell survival and motility. 
Overall aim of this study: to characterise the biological significance of EphB4 receptor in 
the development and progression of endometrial cancer and elucidate the underlying 
mechanisms which contribute to the key cellular events. 
The specific aims of this thesis work are: 
1. To establish an appropriate 3D cell culture system for modelling endometrial 
adenocarcinomas in vitro. 
2. To investigate the expression of EphB4 receptor and its cognate ligand ephrin-B2 in 
human endometrial tissue specimens and epithelial cell lines. 
3. To determine the effects of both kinase-dependent and kinase-independent EphB4 
forward signalling on cell survival and motility in endometrial cancer. 
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Chapter 2    Materials and Methods 
General materials and methods used in this study are outlined in this chapter. Additional 
methods specific for a chapter are described in the relevant chapter.   
2.1 Chemicals and reagents 
All chemicals and reagents used in this study were of analytical grade or cell culture grade 
and were used as received without any further purification. All chemicals and reagents 
including laboratory plasticware and glassware were purchased from a range of qualified 
suppliers. Further details are listed in the following text where applicable. 
2.2 Antibodies 
Antibodies used in this study are summarised in Table 2.1. 
 
Table 2.1 Summary of primary and secondary antibodies used in Western blotting 
Antibody Supplier (Cat #) Host Application 
Primary Antibody    
EphB4 R&D Systems, Minneapolis, 
MN, USA (AF3038) 
Goat WB: 1/2,000 
FAK Upstate, Lake Placid, NY, 
USA (05-537) 
Mouse WB: 1/1,000 
Src Upstate (05-184) Mouse WB: 1/1,000 
p-Paxillin (Tyr118) Upstate (07-733) Rabbit WB: 1/2,000 
GAPDH Abcam, Cambridge, MA, USA 
(ab8245) 
Mouse              WB: 1/5,000 
β-Tubulin Abcam (ab6046) Rabbit WB: 1/2,000 
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p-FAK (Tyr397) Abcam (ab4803) Rabbit WB: 1/1,000 
Paxillin Cell Signalling Technology, 
Beverly, MA, USA (2542) 
Rabbit WB: 1/1,000 
p-Src (Tyr416) Cell Signalling Technology 
(2101) 
Rabbit WB: 1/1,000 
Src Cell Signalling Technology 
(2109) 
Rabbit WB: 1/1,000 
Secondary Antibody    
Goat IgG-HRP Invitrogen, Carlsbad, CA, 
USA (81-1620) 
Rabbit WB: 1/5,000 
Mouse IgG-HRP  Amersham Biosciences, 
Piscataway, NJ, USA 
(NA9310) 
Sheep WB: 1/10,000 
Rabbit IgG-HRP Amersham Biosciences 
(NA9340) 
Donkey WB: 1/10,000 
Human IgG, Fcγ Jackson ImmunoResearch, 
West Grove, PA, USA (109-
005-008) 
Goat Ligand clustering 
WB: Western blotting; p-: phospho-; -HRP: horseradish peroxidase conjugated 
 
2.3 Clinical samples 
A diverse collection of human endometrial tissue specimens were obtained from women 
undergoing hysterectomy at the Greenslopes Private Hospital (Queensland, Australia). 
Ages of patients ranged from 43 to 77 years. The tissue collection protocol was approved 
by the Greenslopes Private Hospital and The University of Queensland human research 
ethics committees and written informed consent was obtained from all patients on the 
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study. All biopsies were examined and characterised by gynaecological pathologists. 
Briefly, normal endometrial tissue biopsies (n=4), premalignant endometrial tissue biopsies 
(n=2), and malignant endometrial tissue biopsies (n=9, 8 cases of endometrioid 
adenocarcinomas, 1 case of papillary serous carcinoma) were included in this collection. 
Tissues were snap-frozen on dry ice and stored at −80°C until RNA extraction was 
performed.  
* Patient samples were collected from the Greenslopes Private Hospital by Dr Jenny 
N.T. Fung previously in our lab.  
2.4 Cell culture 
2.4.1 Cell lines and Maintenance 
A range of established cell lines were employed in this study. The immortalised but non-
malignant human endometrial epithelial cell line, EM-E6/E7/TERT (hereinafter referred to 
as E6/E7) was originally described by Kyo and colleagues (Kyo et al., 2003) and kindly 
provided by Dr Pamela Pollock (Queensland University of Technology, QLD, Australia) 
who received it originally from Dr Kyo (Kanazawa University, Kanazawa, Japan). Three 
human endometrial adenocarcinoma cell lines were used: well-differentiated Ishikawa cell 
line (Sigma-Aldrich, St. Louis, MO, USA), moderately-differentiated HEC-1B cell line and 
poorly-differentiated KLE cell line (American Type Culture Collection, ATCC, Manassas, 
VA, USA). The MCF-7 and MDA-MB-231 human breast cancer cell lines were obtained 
from ATCC. All above cell lines were grown in Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F12, 1:1) media (Invitrogen) supplemented with 10% foetal bovine 
serum (FBS; Invitrogen). Phenol red-free media were used to avoid the oestrogenic 
activity of phenol red. The 293FT cell line which was derived from human embryonal 
kidney cells came as a component included in the ViraPower™ Lentiviral Expression 
System (Invitrogen), and was cultured in DMEM (high glucose) media containing 10% FBS, 
0.1 mM MEM Non-Essential Amino Acids (NEAA), 6 mM L-glutamine, 1 mM MEM Sodium 
Pyruvate and 500 µg/ml Geneticin® (Invitrogen). All cell lines were maintained in a 
humidified atmosphere containing 5% CO2 at 37 °C, and were tested to be free from 
Mycoplasma contamination. All the studies were carried out within 6 cell passages. 
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* The 293FT cells were maintained by Dr Samantha Stehbens in the Pollock 
laboratory (Queensland University of Technology, QLD, Australia). 
2.4.2 2D monolayer culture 
For 2D monolayer cultures, cells were propagated on tissue culture plastic and grown as 
adherent monolayers in appropriate media as mentioned in section 2.4.1. Thawing, 
subculturing and cryopreservation of above mentioned cell lines were performed following 
the instructions from the original cell line providers. 
2.4.3 3D reconstituted basement membrane (rBM) culture 
For 3D rBM cultures, the “on-top” assay described by Debnath and colleagues (Debnath et 
al., 2003) was adopted with some modifications. Briefly, cells were harvested from 
monolayer culture, rinsed with PBS and resuspended in growth media as dispersed single 
cells. Freshly prepared single cells were seeded at a density of 1.0 - 2.5 × 105 cells/ml on 
top of a 1 - 2 mm layer of Matrigel™ basement membrane matrix (BD Biosciences, North 
Ryde, NSW, Australia), and overlaid with growth media containing 2% (v/v) Matrigel. 
Equivalent batches of Matrigel were used throughout the experiments. All 3D rBM cultures 
were normally maintained for 6 to 9 days with media replaced every 3 days. For 
morphological evaluation assays, cells (1- 2.5 × 104) were seeded in 96-well plates as 
miniaturised 3D cultures. For RNA extraction preparation, cells (2 - 5 × 105) were 
inoculated in 35 mm culture dishes as 3D bulk cultures and cellular structures were 
released from Matrigel using Cell Recovery Solution (BD Biosciences) prior to lyses. 
2.4.4 3D spheroid culture on poly-HEMA 
Poly-HEMA hydrogel (Sigma-Aldrich) were used to prevent cells from adherent growth. 
Reproducible 3D multicellular spheroids (MCSs) were generated with this model system 
following the protocol as described by Phung and colleagues (Phung et al., 2011). Briefly, 
growth surfaces were evenly coated with poly-HEMA solution at a final concentration of 10 
mg/ml in 95% ethanol and allowed to dry prior to use. Cells were then plated at an 
appropriate density as mentioned in section 2.4.3 and overlaid with culture media. Cultures 
were normally maintained for 4 to 6 days with media replaced every other day. 
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2.5 Image acquisition 
Cells were visualised with an inverted light microscope Leica DMi1 (Leica Microsystems 
CMS GmbH, Wetzlar, Germany) and phase-contrast images were taken by acquisition 
software Leica Application Suite (LAS) Version 4.5.0 (Leica Microsystems). Brightness and 
contrast settings were adjusted in the presented images where necessary for a better 
visualisation. 
2.6 Reverse transcription polymerase chain reaction (RT-PCR)  
2.6.1 RNA extraction  
Total RNA was isolated from frozen tissues (post liquid nitrogen processing) and cultured 
cells (at 80 - 90% confluency) by using TRIzol® Plus RNA Purification Kit (Invitrogen) 
according to manufacturer’s instructions. All RNA samples were finally dissolved in 20 μl 
UltraPure™ DNase/RNase-free distilled water (Invitrogen) and treated with TURBO DNA-
free™ Kit (Ambion, Austin, TX, USA). The concentration of RNA was determined by using 
the NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA) and the 
purity was evaluated by calculating the ratios of optical density 260 nm/280 nm and 260 
nm/230 nm. 
2.6.2 cDNA synthesis (RT) 
Single-strand cDNA was reverse transcribed from total RNA (1 µg) in a 20 μl reaction 
using iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, Gladesville, NSW, Australia) 
following the manufacturer’s protocols. Negative controls were prepared by omitting 
reverse transcriptase (no-RT control) and by substitution of water for the template (no 
template control).  
2.6.3 Semi-quantitative PCR 
End-point PCR amplification was performed on a conventional thermal cycler (Corbett 
Research, Concorde, NSW, Australia) with JumpStart™ Taq ReadyMix™ (Sigma-Aldrich). 
Briefly, each PCR reaction mixture contained 2 µl of sample cDNA, 1 × PCR buffer, 200 
µM dNTP mix, 15 pmol of each forward and reverse primer, and 1.25 units of JumpStart™ 
Taq DNA polymerase in a total volume of 25 µl. Thermal cycling conditions included initial 
Chapter 2: Materials and Methods 
 
30 
 
denaturation at 94 °С for 4 minutes, followed by 30 cycles of 94 °С for 30 seconds, 60 °С 
for 30 seconds, and 72 °С for 1 minute and a final extension at 72 °С for 10 minutes. A 
summary of primers used in this study is shown below in Table 2.2. All the primers were 
synthesised commercially at Sigma-Aldrich.  
 
Table 2.2 Oligonucleotides used for PCR amplification 
Transcript  
(GenBank Accession #) 
Primer sequence 
(F: forward; R: reverse, 5’ → 3’) 
Product size  
(bp) 
ERα, ESR1 
a 
(M12674.1) 
F: GACTATGCTTCAGGCTACCATT  
R: TGGTTCCTGTCCAAGAGCAAGTTA 
674 
ERβ, ESR2 
a 
(X99101.1) 
F: TAGTGGTCCATCGCCAGTTATC  
R: GCACTTCTCTGTCTCCGCACAA 
439 
GPR30, GPER1 b 
(U63917.1) 
F: AGTCGGATGTGAGGTTCAG 
R: TCTGTGTGAGGAGTGCAAG 
240 
PR-A/B, PGR c 
(M15716.1) 
F: CGCCCTATCTCAACTACCTG 
R: CCTGACAGCACTTTCTAAGG 
273 
PR-B, PRB  
(NM_000926.4) 
F: TGTGCGTGTGGGTGGCATTCT 
R: TTTGTCCCAGCGAGCGGCAA 
480 
HPRT-1, HPRT1 d 
(M31642.1) 
F: CCTGGCGTCGTGATTAGTGAT 
R: CGAGCAAGACGTTCAGTCCT 
137 
EphA3, EPHA3 e  
(AF213459.1)  
F: GCTGCTCGGAACATCTTGATC  
R: TGGTGATGTCCACCTGATTGG 
138 
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EphA4, EPHA4 e 
(NM_004438.3) 
F: GAAGGCGTGGTCACTAAATGTA  
R: TTTAATTTCAGAGGGCGAAGAC 
1013 
EphB1, EPHB1 e 
(NM_004441.4) 
F: TGTGAGATGGACAGCTCCAGAG  
R: TGCCACAGTCTTGAGACTTGCC 
316  
EphB2, EPHB2 e  
(NM_004442.6)  
F: ATGATCCGCAATCCCAACAGC  
R: CATCATCTGAGACACGACGTC 
201  
EphB3, EPHB3 e  
(NM_004443.3)  
F: GATCCTACCTACACCAGTTCC  
R: ACGGCATTGATGACATCCTGG 
188 
Ephrin-B2, EFNB2 f 
(NM_004093.3) 
F: AAAGTTGGACAAGATGCAAG 
R: TGTACCAGCTTCTAGTTCTG 
81 
EphB4, EPHB4 f 
(NM_004444.4) 
F: TGGTACTAAGGTCTACATCG 
R: CGATCTCTTTTGCAAATTCC 
77 
HPRT-1, HPRT1 f 
(M31642.1) 
F: CTAATTATGGACAGGACTGAAC 
R: AGCAAAGAATTTATAGCCCC 
108 
β-Actin, ACTB f 
(NM_001101.3) 
F: GACGACATGGAGAAAATCTG 
R: ATGATCTGGGTCATCTTCTC 
131 
a (Hillier et al., 1998); b (He et al., 2009); c (Aldad et al., 2011); d (Rey et al., 2000); e 
(Hogerheyde et al., 2013); f KiCqStart™ primers (Sigma-Aldrich) used in real-time PCR  
 
Semi-quantitative PCR was performed by simultaneously amplifying the gene of interest 
along with the housekeeping gene Hypoxanthine phosphoribosyl transferase 1 (HPRT1) in 
the same end-point PCR reaction. HPRT1 has been indicated as one of the most stably 
expressed housekeeping genes in a variety of endometrial cell lines and the human 
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endometrium (Vestergaard et al., 2011), and therefore was used as the internal control for 
gene quantification in this study. Gene-specific signal was then compared to the internal 
control signal amplified from the same sample. A method previously referred to as the 
“primer-dropping” method (Wong et al., 1994) was applied in which different sets of 
primers were added at different cycles during the PCR reaction. The point (a certain cycle 
number) where a primer set were dropped was adjusted for individual gene transcripts to 
assure that both the gene of interest and the internal control were amplified within the 
exponential phase at sub-saturating levels by the end of the PCR reaction. In this way, 
meaningful semi-quantitative data could be obtained for detecting relative expression of 
each specific transcript and comparing transcript abundance across multiple samples. For 
co-amplifications performed in this study, mRNA transcripts for ERα, GPR30, PR-A/B, and 
PR-B were amplified by 30 cycles; ERβ amplified by 32 cycles; and HPRT1 amplified by 26 
cycles. An annealing temperature of 60 °С was tested to be optimal for above co-
amplifications.  
After PCR reaction, the products were resolved by electrophoresis on a 2% agarose gel 
containing 0.5 μg/ml ethidium bromide (Sigma-Aldrich), and visualised under UV 
illumination. Images were captured using Quantity One software (Bio-Rad Laboratories) 
and densitometry analysis was performed using ImageJ software (National Institutes of 
Health, NIH, Bethesda, MD, USA). Transcriptional expression levels of a specific gene 
across multiple samples were normalised against the internal control HPRT1.  
2.6.4 Real-time quantitative PCR 
Real-time quantitative PCR was carried out in MicroAmp® 96-well plates (Applied 
Biosystems, Foster City, CA, USA) using 2 × SYBR® Green Master Mix (Applied 
Biosystems) with the Applied Biosystems StepOne™ Real-Time PCR System (Applied 
Biosystems) according to the manufacturer’s instructions. Pre-designed KiCqStart® SYBR® 
Green Primers for amplifying human EphB4 (EPHB4), ephrin-B2 (EFNB2), HPRT-1 
(HPRT1) and β-Actin (ACTB) were purchased from Sigma-Aldrich. Prior to quantitative 
RT-PCR, end-point RT-PCR was performed to confirm the absence of genomic DNA using 
two different housekeeping genes, β-Actin and HPRT-1, respectively. PCR conditions 
were optimised to allow amplification efficiency of each gene transcript to reach close to 
100% (95% - 105%). Melting curves were checked to confirm the purity of the amplified 
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products. Differences in EPHB4 or EFNB2 gene expression between compared sources of 
mRNA were quantified based on 2- (ΔCT sample−ΔCT control) method as described by Livak and 
Schmittgen (Livak and Schmittgen, 2001) and normalised against the internal control, 
HPRT1. 
2.7 Immunoassays  
2.7.1 Protein extraction 
Whole-cell lysates were prepared by extracting 2D and 3D cultured cells (1 × 107) in 500 µl 
of lysis buffer consisted of 150 mM sodium chloride, 50 mM Tris-HCl (pH 7.4), 1% nonyl 
phenoxylpolyethoxylethanol supplemented with 1 × CompleteMini™ protease inhibitor 
cocktail (Roche Diagnostics, Castle Hill, NSW, Australia) and phosphatase inhibitors (10 
nM sodium fluoride, 1 mM sodium orthovanadate, and 10 mM tetrasodium pyrophosphate; 
Sigma-Aldrich) on ice for 30 minutes before cleared by 12,000 × g centrifugation at 4°C. 
Total protein concentration was determined using a Pierce™ BCA assay kit (Thermo Fisher 
Scientific Australia Pty Ltd), and absorbance at 560 nm was measured with Spectra 
Rainbow spectrophotometer, X-Read Plus Version 4.3 (Tecan, Crailsheim, Germany). 
Lysates were processed immediately or aliquoted and stored at –80 °C to avoid repeated 
freeze-thaw cycles. 
2.7.2 Western blotting 
Proteins (30 µg) of each lysate sample were mixed with 5 × sample buffer (250 mM Tris-
HCl, pH 6.8, 8% sodium dodecyl sulfate, 30% glycerol, 20 mM dithiothreitol, 0.02% 
bromophenol blue and 10% 2-mercaptoethanol; Sigma-Aldrich) and heated at 95 °C for 5 
minutes. Protein samples were then separated on a 7.5% or 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel before transferred onto BioTrace™ 
pure nitrocellulose blotting membranes (Pall Corporation, Cheltenham, VIC, Australia). 
Membranes were blocked for 1 - 2 hours with 5% skim milk powder in Tris-buffered saline-
0.1% Tween-20 (TBS-T, pH 7.6) prior to incubation with primary antibodies overnight at 
4°C. Membranes were washed in TBS-T and incubated for 1 hour at room temperature 
with HRP-conjugated secondary antibodies followed by detection with enhanced 
chemiluminescence (Thermo Fisher Scientific Australia Pty Ltd) according to the 
manufacturer’s instructions. Western blotting analyses were carried out using the 
Chapter 2: Materials and Methods 
 
34 
 
antibodies listed in Table 2.1. Precision Plus Protein™ Kaleidoscope™ prestained 
standards (Bio-Rad Laboratories) were used as MW markers. β-Tubulin and GAPDH were 
used as loading controls to ensure equivalent loading and transfer of proteins and allow 
semi-quantitative densitometry analysis on scanned films using ImageJ software (NIH). 
2.7.3 Enzyme-linked immunosorbent assay (ELISA) 
Tyrosine-phosphorylated EphB4 levels in cell lysates were measured by Human Phospho-
EphB4 DuoSet IC kit (R&D Systems) developed from a sandwich ELISA assay and 
performed using Costar® 96-well EIA/RIA plates (Life Technologies, Mulgrave, VIC, 
Australia). Briefly, cell lysates were prepared in supplied Lysis Buffer (107 cells/ml) as 
described in section 2.7.1. Plates were pre-coated with anti-human EphB4 capture 
antibody. Cell lysates or recombinant human phospho-EphB4 standard peptides at 
different concentrations were loaded in a total volume of 100 µl per well. Biotinylated anti-
phospho-tyrosine detection antibody was then added to the well and the plate was 
incubated 2 hours at room temperature in the dark. After that, the plates were washed and 
the specific immunoreactivity was determined by the HRP–streptavidin–
tetramethylbenzidine detection system. The reactions were stopped by addition of 50 µl 2 
M sulphuric acid. Absorbance was then measured at 450 nm and corrected with readings 
at 570 nm using a microplate reader (Tecan). Human phospho-EphB4 concentrations 
(pg/ml) in cell lysates were quantified by comparing their absorbance readings to the 
standard curve, normalised to the protein content of the lysates (µg/ml).  
2.8 Cell proliferation assay (MTS assay) 
Cells were seeded into 96-well plates at 2 × 103 cells/well and the number of viable cells at 
a certain time point after plating was quantified using CellTiter 96® Aqueous One Solution 
Cell Proliferation Assay (Promega Australia, Alexandria, NSW, Australia) which contains 
tetrazolium compound [3-(4,5-dimethylthiazol2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] (MTS), according to the manufacturer’s protocols. 
Cell viability was determined by measuring absorbance at 490nm with a microplate reader 
(Tecan) and expressed as percentage (%) relative to corresponding controls. Background 
readings from wells with media only were subtracted from the absorbance measurements.  
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2.9 Soft-agar colony formation assay 
Anchorage-independent growth was evaluated by using a two-layer soft agar system 
performed in 6-well plates. Single-cell suspensions were mixed with 0.3% soft agar in 
growth media and seeded at 2.5 × 103 cells/well on top of a layer of 0.6% soft agar 
prepared in growth media. Media was replenished every 3 days. After 3 weeks, colonies 
developed from a single cell on soft agar were fixed with 4% PFA for 20 minutes and 
stained with 0.05% crystal violet (Sigma-Aldrich) at room temperature for 1 hour. The 
stained colonies were visualised under a stereoscopic microscope (Nikon, Japan) and 
colonies which were larger than 100 µm in diameter were counted as positive. A 
microscope stage micrometer (1 DIV = 0.01mm; ProSciTech, Thuringowa, QLD, Australia) 
was used for calibration. Representative images were also taken for each well using a light 
microscope (Leica Microsystems).  
2.10 Wound-healing migration assay 
Cells were seeded at 3 × 104 cells/well into 96-well plates and allowed to form a confluent 
monolayer overnight. Cells were starved in serum-free media for 6 hours before wounds 
were introduced. Uniformed scratch wounds were produced by using the 96-pin 
WoundMaker™ (Essen BioScience, Ann Arbor, MI, USA). Cells were rinsed with PBS to 
remove cell debris and then replaced in serum-free media in order to exclude cell 
proliferation effects during the wound healing process. Images for each assayed well were 
captured from the time point of 0 hour (0 h, immediately after wounding) and every 1 hour 
afterwards up to 24 hours by IncuCyte™ kinetic live cell imaging system (Essen 
BioScience). The wound width was measured using arbitrary units with the use of ImageJ 
software (NIH): five straight lines were made across the wound area on a single 
photograph; the length of the lines was shown in arbitrary units. The average value of 
them was calculated and taken as one measurement. Cell migration at the time point of 20 
hour (20 h) after wounding was then quantified and expressed as relative wound closure 
(%) – [(the initial wound width, 0 h - the wound width, 20 h) / the initial wound width, 0 h × 
100%]. In this case, the value is set to 0% at the time point of 0 h; and 100% when the 
wound is fully closed.  
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2.11 Chimeric ligand ephrin-B2 stimulation assay 
Ishikawa cells were seeded into 96-well plates or 6-well plates at a density of 1 × 105 
cells/ml in complete media and cultured for 48 hours. Cells were starved in serum-free 
media for 24 hours before stimulated with 3 µg/ml chimeric ligand ephrin-B2 clustered with 
goat anti-human IgG (Fc) at a ratio of 1:5. As negative controls, cells were treated with 
PBS or Fc alone. Cells were then subjected to phospho-EphB4 ELISA assay or cell 
proliferation assay as described in sections 2.7.3 and 2.8, respectively.  
2.12 Steroid hormones treatment 
For hormonal treatments, steroid hormones 17β-oestradiol (E2) and progesterone (P4) 
(Sigma-Aldrich) were reconstituted in absolute ethanol at a stock concentration of 1 mM 
and stored in aliquots at -20°C. Cells were plated into 96-well plates at a density of 2 × 103 
cells/well and left to grow for 4 days, during which spheroids develop in 3D cultures, before 
steroid hormones or vehicle controls (0.1% v/v ethanol) were added. Hormones were then 
added to culture media at the specified dosages according to the dose-response assays 
performed earlier, 10 nM E2, 1 µM P4 or a combination of E2 and P4 as indicated. After 
incubation for 48 hours, cell viability was measured by the MTS assay as described in 
section 2.8 and the results were expressed as a percentage (%) relative to vehicle 
controls.  
2.13 Generation of stable cell lines 
2.13.1 Generation of stable EphB4-knockdown endometrial cancer cell lines 
Two validated MISSION® short hairpin RNA (shRNA) pLKO.1-puro constructs targeting 
different exons of human EPHB4 (NM_004444) (Catalogue No: TRCN0000001773; 
TRCN0000001774) were purchased from Sigma-Aldrich. A non-targeting shRNA 
sequence that has no known target in the mammalian genome (5’-
CCGCAGGTATGCACGCGT-3’) as previously described by Bryant and colleagues (Bryant 
et al., 2010), was used as a negative control. Lentiviruses were produced in 293FT cells 
using the ViraPower™ II Lentiviral Gateway® Expression System (Invitrogen) and the viral 
stocks were stored in small aliquots at -80°C for titration and cell transduction.  
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* Preparation of above lentiviral stocks was performed by Mr Robert Ju and Dr 
Samantha Stehbens in the Pollock laboratory (Queensland University of 
Technology, QLD, Australia). 
Ishikawa and HEC-1B endometrial cancer cells were plated into 6-well plates at a density 
of 5 × 105 cells/well and transduced with freshly prepared lentiviruses at 70 - 80% 
confluency. Briefly, lentiviruses containing EPHB4-shRNA constructs or non-targeting 
control shRNA construct were added to cells in growth media containing 2 µg/ml polybrene 
(Sigma-Aldrich). Cells were replaced in fresh growth media 24 hours after infection. After a 
further 24 hours, cells were selected in growth media containing 2.5 µg/ml puromycin 
(Sigma-Aldrich) for 2 weeks to acquire stable lentiviral shRNA-transduced cell lines. Non-
transduced cells served as controls during the antibiotics selection to verify the 
transduction efficiency. Successful knockdown of EphB4 proteins in above cell lines was 
confirmed by Western blotting. Stable lentiviral shRNA-transduced cell lines were used for 
further functional studies. 
2.13.2 Generation of stable EphB4-overexpressing endometrial cancer cell lines  
Two validated plasmid constructs as previously described by Rutkowski and colleagues 
(Rutkowski et al., 2012), pIRES-B4 (B4; inserted with full-length coding sequence of 
human EPHB4, NM_004444) and empty vector (EmV) pIRES-neo2, were kindly provided 
by Dr Sally-Anne Stephenson (Queensland University of Technology, QLD, Australia). The 
two plasmid constructs were amplified in Escherichia coli and purified using Endotoxin-free 
plasmid DNA purification kit (NucleoBond® Xtra Midi EF / Maxi EF; MACHEREY-NAGEL 
GmbH & Co. KG, Dũren, Germany) according to the manufacturer’s instructions. 
Concentration of plasmid DNA was measured using the NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific Australia Pty Ltd) and the purity was 
evaluated by calculating the ratios of optical density 260 nm/280 nm.  
 
HEC-1B cells were plated into a 6-well plate at 5 × 105 cells/well and transfected with 
purified plasmids B4 and EmV when cells reached 70 - 80% confluency. The transfection 
reaction was performed with a transfection reagent volume to DNA mass ratio of 3:1 using 
Lipofectamine 2000 (Invitrogen) following the manufacturer’s protocols. Cells were 
replaced in fresh growth media 24 hours after transfection and then replaced with growth 
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media containing 1 mg/ml of Geneticin® (G418; Invitrogen) for 2 weeks to select stably 
transfected cell lines. Overexpression of EphB4 proteins in HEC-1B cell line was 
confirmed by Western blotting. Stable transfected cell lines were used for further functional 
studies. 
2.14 Statistical analysis 
Data are presented as mean ± standard deviation (SD) unless otherwise stated. Two-way 
or One-way ANOVA analysis followed by selective post-hoc test was used for multiple 
comparisons. Unpaired two-tailed Student’s t-test was used for the comparison between 
two groups. A p-value < 0.05 was considered to be statistically significant. Statistical 
analyses were conducted using GraphPad Prism 6 Version 6.00 software (GraphPad 
Software, La Jolla, CA, USA). 
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Chapter 3    Modelling human endometrial cancer 
in vitro with the 3D architecture 
3.1 Introduction 
Cancer cell lines established from primary tumours are widely used as in vitro model 
systems for studying tumour cell biology. In vitro studies in cancer cells are traditionally 
performed with cells cultured on flat (2D) tissue culture plastic over the past decades. 
Nonetheless, emerging research has shown that a 3D approach is more reliable for 
modelling epithelial cancers in vitro in a structurally appropriate context (Debnath and 
Brugge, 2005). In 3D culture models, the acinar or glandular structures recapitulate the 
architecture and function of native epithelial tissue (Yamada and Cukierman, 2007, Hebner 
et al., 2008). In this regard, 3D cell model systems allow us to obtain new insights into how 
the associated genotypic alterations actually contribute to the histological phenotypes 
observed in vivo. 
Several approaches have been used previously to generate 3D culture models of 
endometrial epithelial cells to gain a better understanding of the carcinogenesis processes 
in the human endometrium. A large amount of multicellular spheroids (MCSs) were 
produced from primary human endometrial cancer cells in a scaffold-free manner by using 
a dynamic rotary cell culture system. These MCSs appeared histologically similar to the 
primary tumours. Proteomic profiling identified several differentially expressed tumour 
markers between 2D and 3D cultures (Grun et al., 2009). Alternatively, endometrial 
epithelial structures could be modelled in static liquid overlay systems using hydrogel-
based matrices. When plated on Matrigel™ (Engelbreth–Holm–Swarm tumour-derived 
basement membrane matrix), Ishikawa cells aggregated to form glandular-appearing 
tubular and spherical structures. A specific cell-cell interaction between the Ishikawa cells 
and co-cultured stromal cells was identified in the 3D cultures but not in 2D monolayers 
(Arnold et al., 2002). A novel culture system using a very small volume of Matrigel was 
proposed in a later study (Eritja et al., 2010). Promising results were achieved in their 
published work as primary mouse endometrial epithelial cells successfully formed well-
polarised acinar spheroids. Other than the natural hydrogels of animal origin, synthetic 
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hydrogels have also been used (Knight and Przyborski, 2014). Distinct 3D multicellular 
structures were developed from different endometrial cancer cell lines cultured on non-
adherent surfaces using poly-HEMA hydrogel. The 3D structures exhibited greater 
resistance to the anti-cancer drugs than 2D monolayers (Chitcholtan et al., 2012). In an in 
vitro 3D spheroid model of endometriosis which was recently established by Brueggmann 
and colleagues (Brueggmann et al., 2014), the biological features of human endometriosis 
lesions were more closely mimicked by the ovarian endometriosis epithelial cells cultured 
on poly-HEMA hydrogel compared to 2D monolayer cultures. Each of the above systems 
has its own advantages and disadvantages in the application of 3D modelling (Kim, 2005) 
and the selection of an appropriate system should be determined by the specific 
experimental outcomes demanded for a given study. 
Thus, in an effort to develop an appropriate monotypic 3D cell model system used for 
further investigating the role of EphB4 in endometrial adenocarcinoma cells, a number of 
3D modelling approaches were studied and the relevant works are described in this 
chapter. 
3.2 Methods 
3.2.1 2D monolayer culture 
The E6/E7-hTERT (E6/E7) non-malignant human endometrial epithelial cell line (Kyo et al., 
2003) and the human endometrial adenocarcinoma cell lines, Ishikawa (well 
differentiated), HEC-1B (moderately differentiated) and KLE (poorly differentiated) were 
studied. The MCF-7 and MDA-MB-231 human breast cancer cell lines were also included 
as controls. Culture conditions for maintenance of above cell lines were indicated in 
section 2.4.1. For routine cultures, cell lines were grown in basal media phenol red-free 
DMEM/F12 (1:1) supplemented with 10% FBS (hereinafter referred to as complete growth 
media, CGM). For serum-free cultures, cell lines were grown in serum-free media (SFM) 
consisted of basal media supplemented with 1‰ BD™ ITS Universal Culture Supplements 
Premix (containing insulin, human transferrin and selenous acid) and 5 ng/ml hEGF (BD 
Biosciences). 
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3.2.2 Establishment of 3D rBM culture with Matrigel 
To establish an optimal 3D culture system for endometrial adenocarcinoma cells, a 
number of modelling approaches with the use of laminin-rich Matrigel matrix were 
investigated in the Ishikawa and KLE cell lines. For 3D cultures employing Matrigel as a 
rBM, an “on-top” protocol based on the method previously developed by Debnath and 
colleagues (Debnath et al., 2003) was used. As described in section 2.4.3, cells were 
propagated on top of a thick (1 - 2 mm) layer of Matrigel (hereinafter referred to as “3D 
thick on-top”). Two slightly different protocols were also performed for comparisons by 
which cells were cultured on top of a thin (0.5 mm) layer of Matrigel (hereinafter referred to 
as “3D thin on-top”) or totally embedded in the Matrigel (hereinafter referred to as “3D 
embedded”) as described by Lee and colleagues (Lee et al., 2007). In addition, a relatively 
novel approach established more recently by Eritja and colleagues (Eritja et al., 2010) was 
adopted. The name of “3D Overlay” culture was used here in order to be distinguished 
from above 3D rBM cultures. In this model system, cells were overlaid with SFM 
containing only 3% (v/v) Matrigel however without an underlying bed of gelled matrix.  
Phenol red-free regular Matrigel in CGM was used to optimise culture conditions. To 
achieve more defined culture conditions, growth factor-reduced phenol red-free Matrigel 
(GFR-Matrigel) prepared in SFM was used. Equivalent batches of Matrigel were used. 
Morphogenesis of Ishikawa and KLE cells grown in above 3D culture systems were 
monitored for up to 15 - 20 days with media replaced every 2 to 4 days. Concentrations of 
Matrigel used in modelling and appropriate seeding cell density were optimised to 
establish the working protocols. For morphological evaluation and RT-PCR analysis 
performed in above 3D cultures, cells were prepared as outlined in section 2.4.3.  
3.2.3 Generation of 3D spheroids on poly-HEMA 
Reproducible 3D spheroids were generated by culturing cells on adherent-resistant poly-
HEMA hydrogel as described in section 2.4.4. Cultures were maintained in CGM for 4 to 6 
days. 
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3.2.4 Hormonal assays 
Steroid hormones oestrogen and progesterone play the pivotal roles in orchestrating 
hormone-related cellular signals which are closely involved in the development and 
malignant progression of endometrial cancer. As a major functional characteristic in the 
endometrial glandular epithelial cells, hormonal response in Ishikawa and KLE cell lines 
was thus compared between 2D monolayers and 3D rBM models. Steroid hormones 
responsiveness in the two different cell lines was first evaluated by dose-response assays. 
Cells were incubated with various concentrations of 17β-oestradiol (E2) and progesterone 
(P4) over a period of 72 hours. Cell viability at different time points (24 h, 48 h and 72 h) 
was then measured by the MTS assay as outlined in section 2.8 to determine the optimal 
dosages for hormonal treatments.  
The hormone-responsive Ishikawa cells modelled in 2D monolayer culture and 3D rBM 
culture were then treated with E2 and P4 as indicated in section 2.12. Cells were hormone 
deprived in basal growth media DMEM/F12 for 24 hours before exogenous E2 and P4 
hormones were added. To represent the antagonistic effect of P4 on E2-induced epithelial 
proliferation in the human endometrium, administration of the two steroids were performed 
as demonstrated below in Figure 3.1. Cells were subjected to cell viability assessment and 
semi-quantitative RT-PCR analysis at the end of the treatments. Cells treated with vehicle 
controls were used as control samples for multiple comparisons.  
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Figure 3.1 Schematics of oestrogen (E2) and progesterone (P4) hormonal treatments 
performed in Ishikawa endometrial adenocarcinoma cells  
Cells were plated on Day 0 at a density of 1.0 × 104 cells/ml and allowed to grow as a 2D 
monolayer on plastic or form multicellular structures in 3D rBM cultures with Matrigel. Cells 
were hormone deprived the day (Day 4) before treatments were introduced. On Day 5, 
cells were treated with vehicle control (0.1% ethanol), or E2 alone (10 nM), or a 
combination of E2 and P4 (primed with 10 nM E2 for 24 h followed by concomitantly treated 
with 10 nM E2 and 1 µM P4). Treatments were replenished after a further 24 hours (Day 6). 
Cells were subjected to further assessment in another 48 hours (Day 8). 
 
3.2.5 RT-PCR 
Hormonal treatment-induced changes in oestrogen (ER) and progesterone (PR) receptors 
status were further examined. Expression of ER and PR transcripts (ESR1, ESR2, 
GPER1, PGR and PRB) in 2D and 3D modelled Ishikawa and KLE cell lines were detected 
by RT-PCR analysis as described in section 2.6. Primers of each amplicon used in PCR 
amplification are listed in Table 2.2. Relative mRNA expression of different ER and PR 
isoforms in a variety of cell samples were determined by semi-quantitative PCR as 
described in section 2.6.3 based on densitometry analysis and normalised to an 
oestrogen-independent housekeeping gene HPRT1 (Rey et al., 2000). Ishikawa cells 
grown in 2D monolayers were used as the calibrator sample for multiple comparisons. 
Results are expressed as ratios relative to the specific mRNA abundance in the calibrator 
sample.  
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3.3 Results 
3.3.1 Establishment of an optimal 3D rBM culture protocol 
The well-differentiated Ishikawa endometrial cancer cell line was used for optimising 
culture conditions applied in 3D rBM systems. This cell line has been suggested to 
manifest characteristics which resembles a glandular phenotype of human endometrial 
epithelium (Kuramoto and Nishida, 2003). As demonstrated in Figure 3.2a, Ishikawa cells 
were prepared in single-cell suspensions and cultured in 3D rBM systems using three 
different protocols as described in section 3.2.2: (1) “3D thick on-top”; (2) “3D thin on-top”; 
(3) “3D embedded”. The morphogenesis of 3D cellular structures in the three model 
systems were compared thereafter in parallel. Cells cultured on plastic served as 2D 
controls. 
Strikingly, as shown in Figure 3.2b, Ishikawa cells assumed markedly different morphology 
in 3D rBM culture systems as compared to the cobblestone-like monolayers they formed in 
traditional 2D culture. Unanimously, in the three different 3D rBM culture systems being 
investigated here, the well-differentiated Ishikawa cells formed compact acinar spheroids 
consistent with restored cell polarity, which were reminiscent of the glandular epithelium 
phenotype. A central hollow lumen was commonly visible within an individual multicellular 
spheroid (MCS) structure by Day 5 or Day 6 of culture. Individual spheroids kept 
increasing in size up to Day 15 and some of them developed into a film of meshwork-like 
structures in which acinar spheroids were connected to one another through branching 
tubular structures. 
For cells grown in these 3D rBM culture systems, the degree of colony organisation and 
acinar formation were taken into account in visual evaluation. At least five images from 
triplicate wells of each culture condition were captured and analysed. Overall, we found in 
our study that the “on-top” protocols were generally more reproducible and more efficient 
in formation of acinar MCSs than the embedded protocol. A slower cell proliferation rate 
was observed with Ishikawa cells grown in the “3D embedded” rBM system in comparison 
to cells grown in the other two “on-top” rBM systems. This was indicated by both the size 
and amount reached in the formation of MCSs as inspected. Nevertheless, with “3D thin 
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on-top” protocol, substantial monolayer cells were observed underneath the 3D bulk 
structures before the central lumens became prominent (see Day 15, Figure 3.2b).  
Taken together, the “3D thick on-top” protocol is capable of providing more consistent 
acinar MCSs morphogenesis for downstream analyses. As a result, it was established as a 
preferred protocol in the following experiments described in this chapter for modelling 
endometrial adenocarcinomas in the 3D rBM culture system. 
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Figure 3.2 Ishikawa endometrial epithelial cells assumed markedly different 
morphologies under different culture conditions  
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(a) Schematics of different modelling approaches. Ishikawa cells were grown on plastic 
(2D) or in the 3D rBM cultures following (from left to right): the “3D embedded”, the “3D 
thin on-top”, and the “3D thick on-top” protocol, respectively as described in section 3.2.2. 
Image (a) is modified from (Lee et al., 2007). (b) Micrographs of phase-contrast images 
taken at indicated time points from Ishikawa cells grown under different conditions as 
illustrated in (a) over a period of 15 days. Each micrograph in the panel is representative of 
the overall size of acinar spheroids generated from a single cell or small clumps of cells on 
the day specified. On Day 0, cells were seeded as single cells at the same density across 
different model systems (data not shown). Day 1 - 3, cells started to form small aggregates 
or clumps in 3D rBM cultures. Day 5 - 7, cells proliferated to form various acinar spheroids 
in 3D rBM cultures, with an evident central lumen (black arrows). After that, individual 
spheroids kept increasing in size up to Day 15 and some further expanded to form 
meshwork-like structures. Monolayer culture was discontinued by Day 6 of culture as cells 
reached full confluency. Images were taken by light microscopy at an original 
magnification of 20 ×, scale bar = 50 µm. 
 
As the Matrigel matrix is quite expensive, we then sought to further optimise the 
concentration used in modelling, alongside the ideal seeding numbers of cells. Since 
Matrigel (10 - 12 mg/ml) could not solidify properly at a concentration lower than 50% (v/v), 
the matrix was prepared in DMEM/F12 media and tested over a range of concentrations 
(50 – 100%, v/v). No evident differences were noted across different concentrations of 
Matrigel in the results of MCSs morphogenesis (Figure 3.3). An optimal seeding density for 
cell proliferation and morphogenesis assessments by 6 to 8 days of 3D rBM culture was 
found in a range of 5 × 104 - 1.0 × 105 cells/cm2, depending on the growth profile of each 
individual endometrial adenocarcinoma cell line (data not shown here). 
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Figure 3.3 Ishikawa endometrial epithelial cells modelled in 3D rBM cultures using 
different concentrations of Matrigel matrix  
Matrigel matrix was prepared in DMEM/F12 media over a range of different concentrations 
(50 - 100%, v/v) and used in the “3D thick on-top” rBM modelling assay. Ishikawa cells 
formed comparable acinar spheroids after 6 days of culture in 3D rBM models regardless 
of the concentration of Matrigel used. Micrographs represent phase-contrast images taken 
from Ishikawa cells cultured as indicated above. Images were taken by light microscopy at 
an original magnification of 10 ×, scale bar = 100 µm. 
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3.3.2 3D rBM culture resembles epithelial structures of endometrial adenocarcinomas 
Regular Matrigel prepared in CGM was used in the 3D rBM modelling optimisations as 
presented above in section 3.3.1, while GFR-Matrigel and SFM were used in the next 
experiments to provide more defined culture conditions. Morphological features of 
Ishikawa and KLE cells in three different model systems: (1) 2D monolayer culture; (2) 3D 
rBM culture using the “thick on-top” protocol; and (3) “3D Overlay” culture were 
investigated.  
Intriguingly, unlike the results mentioned earlier from the mouse endometrial epithelial cells 
(Eritja et al., 2010), our results indicate that the initially deposited gelled matrix which 
underlies the human endometrial epithelial cells seems to be essential for restoration of a 
proper cell polarity. In “3D Overlay” models (Figure 3.4b, far right panel), Ishikawa cells 
formed disorganised multicellular clusters which differed from those polarised acinar 
spheroids seen in the 3D rBM model; while KLE cells failed to form any 3D structures but 
into an extended layer of cells as a distorted branching phenotype. Neither of these two 
cell lines modelled in “3D Overlay” cultures were able to mimick the structural features of 
their in vivo counterparts (Figure 3.4a). However, the glandular epithelial structures in 
endometrial adenocarcinomas, a well-differentiated phenotype which retains the glandular 
elements (Figure 3.4a, top panel) and a poorly-differentiated phenotype in which no glands 
are formed but only solid cell mass (Figure 3.4a, bottom panel), were closely resembled by 
modelling Ishikawa and KLE cells in 3D rBM cultures, respectively. Moreover, subtle 
morphological differences were identified between the Ishikawa and KLE cells in 2D 
monolayer cultures, whereas more profound differences were observed between the 
cellular structures of these two distinct cell lines in 3D rBM cultures. Accordingly, 3D rBM 
culture using the thick “on-top” protocol with 50% (v/v) Matrigel was regarded as a more 
appropriate 3D model system than “3D Overlay” culture and 2D monolayer culture. 
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Figure 3.4 Ishikawa and KLE endometrial adenocarcinoma cells modelled in 3D rBM 
cultures resembled the epithelial structures of endometrial tumors  
(a) Histological structures of two human endometrial adenocarcinomas: a well-
differentiated phenotype retains glandular elements (top); a poorly-differentiated 
phenotype from which the KLE cell line was derived (bottom). Images are adapted from 
(Chatzaki et al., 1994) and (Richardson et al., 1984), respectively. (b) Micrographs of the 
representative images demonstrate the cellular structures developed from the well-
differentiated Ishikawa (top panel) and poorly-differentiated KLE (bottom panel) cells. From 
left to right: cells were modelled in 2D monolayer cultures, 3D rBM cultures using the “thick 
on-top” protocol, and “3D Overlay” cultures, respectively. Images were taken by light 
microscopy at an original magnification of 20 ×, scale bar = 50 µm. 
 
 
 
 
Chapter 3: Modelling human endometrial cancer in vitro with the 3D architecture 
 
51 
 
3.3.3 Gene expression of oestrogen and progesterone receptors is altered in 3D modelled 
endometrial adenocarcinoma cells  
In the human endometrium, steroid hormones oestrogen and progesterone modulate a 
complex set of autocrine and paracrine processes which are believed to be mediated 
through oestrogen (ER) and progesterone (PR) receptors. Expression and distribution 
patterns of ER and PR have been indicated to play an important role in endometrial 
physiology and malignant transformation (Mylonas et al., 2005). To determine whether the 
endometrial MCSs formed in the 3D rBM “thick on-top” model system are functionally 
distinguishable from their 2D counterparts in addition to the distinctions in morphology, we 
investigated ER and PR status of Ishikawa and KLE cell lines when these cells were 
grown in 2D versus 3D conditions. 
The endogenous ER and PR contents in Ishikawa and KLE cell lines were first examined 
using RT-PCR (Table 3.1). Two human breast cancer cell lines MCF-7 
(ERα
+/ERβ
+/GPR30+/PR-A+/PR-B+) and MDA-MB-231 (ERα
-/ERβ
+/GPR30 deficient/PR-A-
/PR-B-) in which ER/PR expression profiles have been characterised before (Subik et al., 
2010, Filardo et al., 2000) were used as references. Gene transcripts of the three ER 
subtypes (ERα, ERβ and GPR30) and the two PR isoforms (PR-A and PR-B) were clearly 
present in Ishikawa cells, whereas KLE cells were found to weakly express ERα and 
GPR30, and express neither isoform of PR. Our results showed a consistency with the 
expression profiles of Ishikawa cells (ER/PR-positive) and KLE cells (ER/PR-negative) 
characterised in earlier work (Richardson et al., 1984, Nishida et al., 1985, Leblanc et al., 
2007). 
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Table 3.1 Transcript profiles of oestrogen and progesterone receptors in a variety of 
human endometrial and breast adenocarcinoma cell lines detected by RT-PCR 
Cell line E/P steroids 
responsiveness 
ERα ERβ GPR30 PR-A/B PR-B 
Ishikawa responsive a + + + + + 
KLE  nonresponsive a WD + WD ND ND 
MCF-7 responsive b + + + + + 
MDA-MB-231 nonresponsive c WD + WD ND ND 
E/P: oestrogen and progesterone; +: clearly detectable; WD: weakly detectable; ND: not 
detectable; a (Kuramoto and Nishida, 2003); b (Levenson and Jordan, 1997); c (Palsson 
and Masters, 1999) 
 
Notably, here we made the novel observation that as identified by semi-quantitative RT-
PCR, transcript levels of these steroid receptors in both Ishikawa and KLE cell lines were 
differentially expressed in 2D versus 3D model systems (Figure 3.5). Relative levels of the 
majority ER and PR transcripts were significantly increased in 3D MCSs compared to their 
2D counterparts (P<0.01), while no significant changes in the transcript levels of GPR30 
and PR-B expressions were identified between 2D and 3D culturing models of Ishikawa 
cells. These results suggest a great impact of the 3D architecture on the modulation of 
relative ER and/or PR isoforms expression pattern in endometrial adenocarcinoma cells.  
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Figure 3.5 Relative mRNA levels of endogenous oestrogen and progesterone 
receptors in Ishikawa and KLE endometrial adenocarcinoma cells detected by semi-
quantitative RT-PCR 
Representative ethidium bromide stained agarose gels showing RT-PCR products of the 
expected size for (a) ERα, (b) ERβ, (c) GPR30, (d) PR-A/B and (e) PR-B mRNA co-
amplified with the housekeeping gene HPRT1. Lanes are as follows: 1, Ishikawa cells in 
2D monolayer cultures; 2, Ishikawa cells in 3D rBM cultures; 3, KLE cells in 2D monolayer 
cultures; 4, KLE cells in 3D rBM cultures; 5, MCF-7 cells in 2D monolayers; 6, MDA-MB-
231 cells in 2D monolayers; 7, no-RT control; 8, no template control. M= marker 
(GeneRuler™ 50bp DNA ladder; Thermo Scientific). Data were collected from two 
biological replicates analysed in technical duplicate. Semi-quantification of relative mRNA 
expression of ER and PR isoforms in above cell samples were quantified as indicated in 
section 3.2.5. Unpaired two-tailed Student’s t-test was used for the comparison between 
paired 2D and 3D cell samples (**P<0.01, ***P<0.001, ****P<0.0001; NS: no significance).  
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3.3.4 Oestrogen and progesterone responses are altered in 3D modelled endometrial 
adenocarcinoma cells  
The regulation of ER and PR gene expression is crucial to oestrogen and progesterone 
actions in steroid hormone-responsive cells. Since the expression pattern of relative 
ER/PR isoforms is greatly altered in the 3D rBM models as demonstrated above, it is likely 
that the 3D architecture can also have an impact on steroid hormone-induced signaling 
responses in endometrial adenocarcinoma cells. To test this theory, cell proliferation in 
response to the oestrogen and progesterone hormone treatments was studied in 2D 
monolayers versus 3D “thick on-top” rBM culturing models of Ishikawa and KLE cells. 
Dose-response experiments showed a significant oestrogen (E2)-induced growth response 
in steroid-responsive Ishikawa cells at a concentration of 10 nM and 100 nM, respectively 
(P<0.01), while progesterone (P4) alone showed no significant effect on the growth of 
Ishikawa cells (Figure 3.6a). However, when concomitantly administered with E2 (10 nM) 
and P4 (1 μM) as described in section 3.2.4, P4 exerted a remarkable antagonistic effect 
on E2-induced cell growth in 2D monolayers (Figure 3.6c left graph, “E2” versus “E2P4”, 
P<0.0001). Interestingly, a less potent inhibitory effect of P4 was observed in 3D rBM 
models (Figure 3.6c right graph, “E2” versus “E2P4”, P<0.05) suggesting that Ishikawa cells 
with the 3D architecture are more resistant to the E2-antagonist effects of P4. On the 
contrary, no significant effect by either E2 or P4 treatment was observed on the growth of 
steroid-nonresponsive KLE cells (Figure 3.6b).  
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Figure 3.6 Effects of oestrogen (E2) and progesterone (P4) on cell proliferation in 
Ishikawa and KLE endometrial adenocarcinoma cells  
Cell viability were determined by the MTS assay in (a) Ishikawa cells and (b) KLE cells 
after incubated with various concentrations of E2 and P4 (0 – 10
4 nM) for 48 hours as 
indicated in section 2.8. (c) Effects of E2 and P4 treatments on the growth of Ishikawa cells 
modelled in 2D and 3D rBM system were determined by the MTS assay as indicated in 
section 2.8. Ishikawa cells in 96-well plates were treated with vehicle control (0.1% 
ethanol), or E2 (10 nM) or E2P4 (10 nM; 1μM) as described in section 3.2.4. Data 
presented in these graphs were collected from two biological replicates analysed in 
technical triplicate. Results are expressed as percentage (%) relative to cells treated with 
vehicle control. One-way ANOVA analysis followed by Turkey’s post-hoc test was used for 
comparison across different treatments (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; NS: 
no significance).  
Chapter 3: Modelling human endometrial cancer in vitro with the 3D architecture 
 
56 
 
Meanwhile, it was found that the relative levels of ER and PR transcripts were regulated in 
a considerably different manner in 2D monolayers versus 3D rBM models (Figure 3.7). It 
has been revealed that different isoforms of ER and PR seem to exert diverse cellular 
functions through modulating separate subsets of target genes (Kumar et al., 1998, Zhang 
et al., 2006, Wei et al., 2012, Arnett-Mansfield et al., 2001). Moreover, ERα, ERβ and PR-A 
are predominantly located to the nucleus and responsible for genomic steroid hormones 
effects (Leslie et al., 2005, Prossnitz and Barton, 2011). Overall, our results implicate that 
the 3D architecture of MCSs modulates the cellular response to hormonal treatments in 
endometrial adenocarcinoma cells by inducing the alterations in relative expression of 
different ER or PR isoforms. 
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Figure 3.7 Transcript expression profiles of different ER and PR isoforms in 
Ishikawa endometrial adenocarcinoma cells in response to oestrogen (E2) and 
progesterone (P4) treatments  
Ishikawa cells (2D monolayers and 3D rBM models) in 6-well plates were treated with 
vehicle control (“C”; 0.1% ethanol), or E2 (“E”; 10 nM) or E2P4 (“EP”; E2 at 10 nM; P4 at 
1μM) as described in section 3.2.4. Representative ethidium bromide stained agarose gels 
showing RT-PCR products of the expected size for (a) ERα, (b) ERβ, (c) GPR30, (d) PR-
A/B and (e) PR-B mRNA co-amplified with the housekeeping gene HPRT1. M= marker 
(GeneRuler™ 50bp DNA ladder; Thermo Scientific). Data were collected from two 
biological replicates analysed in technical duplicate. Relative mRNA expression of ER and 
PR isoforms in above cell samples were quantified as indicated in section 3.2.5 and 
expressed as fold changes relative to the transcript levels in the cells treated with vehicle 
control. One-way ANOVA analysis followed by Turkey’s post-hoc test was used for 
comparison across different treatments (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; NS: 
no significance).  
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3.3.5 Endometrial epithelial cells form multicellular spheroids on poly-HEMA hydrogel 
Although the epithelial structures of endometrial adenocarcinoma have been successfully 
modelled in above 3D rBM system, using a large amount of Matrigel in modelling for the 
remainder of this project was considered to be too costly. Additionally, the animal origin of 
Matrigel and the reported effects in promoting tumor growth and angiogenesis in vivo may 
hinder its use in clinical translation (Boccaccini and Harding, 2011). In this concern, 
synthetic poly-HEMA hydrogel were used as a cost-effective substitution in our study for 
3D modelling as outlined in section 2.4.4.  
As shown in Figure 3.8, endometrial epithelial cells grown on poly-HEMA adopted 
anchorage-independent growth and manifested profoundly different morphology compared 
to 2D monolayers. Surprisingly, distinct phenotypes of 3D epithelial structures comprised 
of collective MCSs were observed with various endometrial epithelial cell lines modelled in 
the 3D poly-HEMA (3D-P) system. The non-malignant E6/E7 cell line which formed 
compact MCSs in the 3D-P system was found to grow much slower than the cells grown in 
2D (data not shown). This phenotype of compact and organised 3D spheroids were also 
observed in the well-differentiated Ishikawa cell line, which were close to the acinar 
structures observed earlier in the 3D rBM system. In contrast, largely disorganised cellular 
structures were generated from the moderately-differentiated HEC-1B cell line and the 
poorly-differentiated KLE cell line. HEC-1B cells formed grape-like clusters, while KLE 
cells formed loosely compacted cellular mass. It seems that these 3D cellular structures 
are in accordance with the differentiation status of each individual endometrial epithelial 
cell line, which suggests that to some extent the intrinsic traits of endometrial epithelial 
cells could be properly modelled in the 3D-P system. Accordingly, poly-HEMA hydrogel 
were used for on-going 3D modelling of endometrial adenocarcinoma cells included in this 
project. 
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Figure 3.8 Endometrial epithelial cells manifested distinct morphologies in 2D 
monolayer and 3D poly-HEMA (3D-P) culture systems  
Micrographs of representative images showing cellular structures generated from a variety 
of endometrial epithelial cell lines. The E6/E7 non-malignant human endometrial epithelial 
cell line and the human endometrial adenocarcinoma cell lines, Ishikawa (well 
differentiated), HEC-1B (moderately differentiated) and KLE (poorly differentiated) formed 
mosaic-like monolayers on plastic (2D; top panel) or formed into different phenotypes of 
spheroids/clusters on poly-HEMA hydrogel (3D-P; bottom panel). Images were taken after 
4 to 6 days of culture by light microscopy at an original magnification of 20 ×, scale bar = 
50 µm. 
 
3.4 Discussion 
MCSs developed from cancer cells is recognised as an established 3D cancer model that 
manifests biological properties close to that of tumours in vivo, such that the reconstructed 
in vitro 3D architecture is thought to be more representative in modelling tumour cell 
structures and functions than traditional 2D cell models. On the other hand, the 3D 
architecture also provides a more defined microenvironment for cancer research in 
contrast to the complex host environment of an in vivo model (Kim, 2005). However, 
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complexity still exists in exploiting an ideal 3D modelling system. Many technical factors 
should be taken into consideration such as cellular origin, composition of ECM and media, 
as well as cell–cell and cell-matrix interactions, and all of them are crucial to interpret 
experimental results (Eritja et al., 2014). Currently, hydrogel-based matrices are most 
commonly used for studying morphogenesis, transformation and carcinogenesis in 3D 
epithelial cell cultures (Knight and Przyborski, 2014).  
In the study described in this chapter, we explored modelling endometrial 
adenocarcinomas in 3D with three major categories of established monotypic systems 
using two different types of hydrogels: (1) 3D rBM culture system using Matrigel; (2) “3D 
Overlay” culture system using Matrigel; (3) 3D poly-HEMA culture system. Human 
endometrial epithelial cells cultured in 3D systems displayed profound changes in 
morphology compared to cells grown in 2D monolayers. Polarised acinar MCSs were 
successfully developed from the well-differentiated Ishikawa cells cultured in 3D rBM or 3D 
poly-HEMA system, but not in the “3D overlay” system. Discrepancy between our results 
and the results presented by Eritja and colleagues (Eritja et al., 2010) could be due to the 
origin and type of endometrial epithelial cells used in the modelling, in which they used 
normal mouse endometrial epithelial cells whereas we used human endometrial cancer 
cells. In addition, endometrial epithelial cells modelled in 3D rBM and 3D poly-HEMA 
systems showed reduced proliferation as compared to cells grown in 2D, which is similar 
to findings from other groups (Fallica et al., 2012, Moll et al., 2013). Furthermore, in either 
of these two types of 3D culture systems distinctive phenotypes of MCSs were presented 
by different endometrial epithelial cell lines, which recapitulate to some extent certain 
biological features of neoplastic transformation and progression of endometrial epithelial 
cells.  
In our study of the 3D rBM modelling system, the structural organisation of the endometrial 
epithelium was resembled by the reconstructed 3D architecture. Moreover, alterations in 
the steroid receptors ER and PR expression were characterised in the 3D cell models in 
comparison to their 2D counterparts. Based on this, the cellular response to hormonal 
stimuli E2 and P4 in Ishikawa cells were found to be differentially modulated between cells 
grown in 3D and those grown in 2D. Taken together, we conclude in our study that the 
reconstructed in vivo-like 3D architecture exhibits distinctive properties from the 2D 
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monolayers not only in the formation of cellular structure but also in the regulation of cell 
proliferation and the relevant gene expressions. It is worth to mention that we performed 
semi-quantitative RT-PCR analysis in this study to screen the expression profile of ERs 
and PRs in Ishikawa and KLE cells by using the “primer-dropping” method (Wong et al., 
1994) which is described in section 2.6.3. Pilot experiments were performed to determine 
the optimal “primer-dropping” cycle and annealing temperature for the amplification of 
individual transcripts, and the optimised parameters are noted in section 2.6.3. This 
approach was used due to limited resources and reduced costs. Ideally, more accurate 
methods, such as real-time quantitative RT-PCR, could be employed to validate these 
data. 
Of note, though it is not fully investigated in this study, discriminations are expected 
between 3D rBM and 3D poly-HEMA systems. The non-malignant E6/E7 cells were found 
to develop a phenotype of protrusive stellate structures in the 3D rBM system (data not 
shown), whereas they maintained as acinar spheroids in the 3D poly-HEMA system. This 
could be attributed to the differences in the composition of the ECMs. In the 3D rBM 
system, endometrial epithelial cells were supported with an inserted layer of basement 
membrane at the initial phase. Various types of growth factors and ECM proteins 
contained in the Matrigel rBM could induce complex cell-cell and cell-ECM interactions. 
Yet in the 3D poly-HEMA system, adherent-free endometrial epithelial cells aggregated to 
form spheroids by the natural tendency without the requirement of external scaffolds, and 
ECMs were deposited by cells spontaneously. In this regard, cell behaviours are largely 
determined by their intrinsic biological properties and so that more physiologically relevant 
cellular events could be experimentally replicated in this model system. Conclusively, the 
3D poly-HEMA in vitro model system presents a more ideal platform than traditional 2D 
monolayer cultures for studying the intricate changes of cell morphology and behaviour in 
the context of endometrium. It also allows us to draw more informative data to characterise 
the underlying molecular mechanisms which are associated with tumour initiation and 
progression in endometrial epithelial cells.  
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Chapter 4    Expression of EphB4 and ephrin-B2 in 
human endometrial specimens and epithelial cell 
lines 
4.1 Introduction 
Receptor tyrosine kinases (RTKs) are the main mediators of the signalling network that 
transmit extracellular signals into the cell and play a crucial role in regulating diverse 
functions in normal cells. Aberrations of these receptors are implicated to participate in 
malignant transformation and tumour proliferation (Bennasroune et al., 2004). In particular, 
erythropoietin-producing hepatocellular carcinoma receptor B4 (EphB4) has emerged as a 
frequently overexpressed RTK in various types of human malignancies. Previous studies 
have demonstrated that EphB4 is overexpressed in human endometrial tumours compared 
to very low or no expressions in normal human endometrium (Takai et al., 2001, Berclaz et 
al., 2003, Alam et al., 2007). Strong epithelial expression of EphB4 and its cognate ligand 
ephrin-B2 was identified in endometrial tumours (Berclaz et al., 2003, Alam et al., 2007). A 
drastic increase of EphB4 proteins in human endometrial hyperplasia was also reported by 
Berclaz and colleagues (Berclaz et al., 2003). Despite the implicated positive correlation 
between EphB4 expression and malignant potential in endometrial cancer, the biological 
significance of EphB4 in endometrial tumorigenesis has not been well characterised. 
Experimental data are desirable to support the correlative data from clinical specimens 
and understand the role of EphB4 in the initiation and progression of human endometrial 
cancer.  
 
Both EphB4 and ephrin-B2 are transmembrane proteins but have been shown to be 
segregated in different membrane microdomains when coexpressed in the MCF-10A 
nontransformed human mammary epithelial cell line (Noren and Pasquale, 2007). 
Interactions between the two proteins largely rely on cell-to-cell contacts where Eph 
receptors are activated in trans upon binding to ephrin ligands (Davis et al., 1994, 
Pasquale, 2005). In addition, activation of EphB4 by its ligand ephrin-B2 has been 
proposed to promote an epithelial phenotype (Noren and Pasquale, 2007). Thus, we 
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hypothesised that EphB4/ephrin-B2 signalling complexes are possibly disrupted in 
endometrial cancer cells which might be resulted from aberrant expression of either or 
both proteins. In this chapter, we examined the expression of EphB4 receptor and its sole 
cognate ligand ephrin-B2 in a collection of endometrial clinical samples and epithelial cell 
lines modelled in 2D monolayers versus 3D MCSs.  
4.2 Materials and Methods 
4.2.1 Clinical samples 
Collection and processing of the fifteen clinically obtained human endometrial tissue 
specimens (n=15) were performed as outlined in section 2.3. Patient characteristics of 
these clinical samples are summarised in Table 4.1. 
 
Table 4.1 Patient characteristics of obtained human endometrial tissue specimens  
Patient 
# 
Age 
(y/o) 
Histopathology record of endometrial biopsy specimen 
  FIGO Grade Histotype Depth of myometrium invasion 
1 46 Benign, basal and 
inactive endometrium 
  
2 56 Benign, but the 
endometrium is of 
disordered 
proliferative type 
  
3 43 Benign endometrium, 
with endometriosis  
  
4 56 Benign endometrial 
polyp, atrophic 
endometrium 
  
5 59 Complex endometrial   
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hyperplasia with 
atypia 
6 58 Complex endometrial 
hyperplasia with focal 
cytologic atypia 
  
7 57 Endometrial 
adenocarcinoma, 
Grade 1   
endometrioid 2 mm out of 10 mm  
8 63 Endometrial 
adenocarcinoma, 
Grade 1 
endometrioid  No invasions identified  
9 56 Endometrial 
adenocarcinoma, 
Grade 1 
endometrioid No invasions identified 
10 58 Endometrial 
adenocarcinoma, 
Grade 1 
endometrioid 4 mm out of 11 mm  
11 67 Endometrial 
adenocarcinoma, 
Grade 1 
endometrioid 2 mm out of 11 mm  
12 55 Endometrial 
adenocarcinoma, 
Grade 1 
endometrioid 8 mm out of 21 mm  
13 77 Endometrial 
adenocarcinoma, 
Grade 2 
 
endometrioid 35 mm out of 35 mm 
14 71 Endometrial 
adenocarcinoma, 
Grade 3 
endometrioid 7.5 mm out of 13 mm  
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15 64 Endometrial 
adenocarcinoma, 
Grade 3 
serous  20 mm out of 22 mm  
 
4.2.2 2D monolayer culture 
A variety of human endometrial epithelial cell lines, including the non-malignant E6/E7-
hTERT (E6/E7) cell line (Kyo et al., 2003), the well-differentiated Ishikawa 
adenocarcinoma cell line, the moderately-differentiated HEC-1B adenocarcinoma cell line, 
and the poorly-differentiated KLE adenocarcinoma cell line were studied. For routine 
cultures, all the cell lines were grown in basal media phenol red-free DMEM/F12 (1:1) 
supplemented with 10% FBS (complete growth media). Additional culture conditions for 
maintenance of above cell lines were indicated in section 2.4.1. 
4.2.3 Generation of 3D spheroids on poly-HEMA 
Three-dimensional (3D) MCSs were generated by culturing the human endometrial 
epithelial cells on adherent-resistant poly-HEMA hydrogel as described in section 2.4.4. 
Cultures were maintained in complete growth media for 4 to 6 days. 
4.2.4 RT-PCR 
Total RNA was extracted from frozen endometrial tissue specimens and 2D cultured 
endometrial epithelial cell lines as outlined in section 2.6.1. Lysates of 3D MCSs were 
prepared in the same manner as 2D cultured cells. Subsequently, cDNA samples were 
generated as indicated in section 2.6.2. Relative expression levels of EPHB4 and EFNB2 
transcripts in the cDNA samples from above tissues and cell lines were determined by 
real-time quantitative PCR using SYBR® Green Master Mix (Applied Biosystems) and 
validated primers (Sigma-Aldrich) as described in more details in section 2.6.4. The E6/E7 
cells grown in 2D monolayers were used as the calibrator sample for multiple comparisons. 
Results are expressed as fold changes relative to the specific transcript abundance in the 
calibrator sample. In addition, expression of several other Eph receptors (EPHA3, EPHA4, 
EPHB1, EPHB2 and EPHB3) which can potentially bind to ephrin-B2 (Pasquale, 2004, 
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Pabbisetty et al., 2007) were also examined in the cDNA samples derived from 2D or 3D 
cell line models by end-point PCR as described in section 2.6.3. Primers of each amplicon 
used in PCR amplification are listed in Table 2.2. Primers used for amplifying EPHA3, 
EPHA4, EPHB1, EPHB2 and EPHB3 were kindly provided by Dr Sally-Anne Stephenson 
from QUT (Brisbane, Australia). 
4.2.5 Western blotting 
Whole-cell lysates were prepared from 2D and 3D cultured endometrial epithelial cell lines 
as described in section 2.7.1. Expression of total EphB4 proteins (~ 120 KDa) in a variety 
of cell samples were detected by Western blotting analysis as described in section 2.7.2. 
After blotting for EphB4, membranes were stripped and reprobed with the β-Tubulin 
loading control (~ 50 KDa) antibody as indicated in section 2.7.2. Antibodies used for this 
study are listed in Table 2.1. Data were collected from three independent experiments 
(biological replicates) and the expression level of total EphB4 in the above samples were 
determined by semi-quantitative densitometry analysis correcting for the loading controls. 
The E6/E7 cells grown in 2D monolayers were used as the calibrator sample for multiple 
comparisons. Results are expressed as fold changes relative to EphB4 protein levels in 
the calibrator sample. 
4.2.6 ELISA  
Tyrosine-phosphorylated EphB4 levels in cell lysates were determined by the human 
phospho-EphB4 ELISA assay as described in section 2.7.3. A standard curve was created 
by plotting the mean absorbance for each standard concentration (x axis) against the 
phospho-EphB4 concentration (y axis) and a best-fit four parameter logistic (4-PL) curve 
was generated by using GraphPad Prism 6 Version 6.00 software (GraphPad Software). 
To obtain accurate calculation of phospho-EphB4 concentrations in the analysed sample 
lysates, appropriate dilutions were made to ensure the phospho-EphB4 concentration in 
each assayed sample stayed within the standard range (31.25 – 4 × 103 pg/ml). 
4.2.7 Drug treatments 
Ishikawa cells were seeded into 96-well plates or 6-well plates at a density of 1 × 105 
cells/ml in complete media and cultured for 48 hours. For 3D spheroids formation, growth 
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surfaces were evenly coated with poly-HEMA as indicated in section 2.4.4. Cells were 
starved in serum-deprived media for 24 hours prior to the addition of clustered chimeric 
ligand ephrin-B2/Fc (3 μg/ml) and/or a selective EphB4 kinase inhibitor NVP-BHG712 (100 
nM; Tocris Bioscience, Bristol, UK). Cells were pre-incubated with NVP-BHG712 at 37 °C 
for 1 hour prior to ligand stimulation. As negative controls, cells were treated with PBS or 
Fc alone. Cell viability after a 48 hour incubation time was measured by the MTS assay as 
described in section 2.8. Tyrosine-phosphorylated EphB4 levels in the cells after 
stimulation with ephrin-B2/Fc for 20 minutes were determined by phospho-EphB4 ELISA 
assays as indicated in section 2.7.3. Increased duration of ephrin-B2/Fc stimulation 
causes a significant decrease in the protein level of EphB4 as well as in the extent of 
receptor phosphorylation (Xia et al., 2005b).  
4.3 Results 
4.3.1 EPHB4 and EFNB2 genes are highly expressed in endometrial adenocarcinomas 
Overexpression of EphB4 and ephrin-B2 in human endometrial adenocarcinomas has 
been detected by RT-PCR and immunohistochemistry in previous work (Takai et al., 2001, 
Berclaz et al., 2003, Alam et al., 2007). To verify these results, we screened a diverse 
collection of human endometrial tissue specimens (n=15) for EPHB4 and EFNB2 gene 
transcripts by real-time RT-PCR. EPHB4 and EFNB2 were found to be coexpressed in all 
the endometrial tissue specimens examined while expression levels of these two genes 
were largely variable (Figure 4.1a and 4.1b). EPHB4 expression was found to be 
consistently higher in endometrial hyperplasia (n=2) and carcinoma tissues (n=9) in 
comparison to little expression in normal endometrial tissues (n=4) (Figure 4.1a). EFNB2 
expression levels were comparably low in normal endometrial tissues but more variable in 
endometrial carcinoma tissues, although in some endometrial carcinoma specimens a 
dramatic increase in transcript levels of EFNB2 was also observed (Figure 4.1b). Overall, 
our results demonstrated that EPHB4 and EFNB2 are highly expressed in human 
endometrial adenocarcinomas which are in accordance with previous findings. 
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Figure 4.1 Expression of EPHB4 and EFNB2 gene transcripts in a collection of 
human endometrial tissue specimens detected by real-time RT-PCR 
Relative mRNA expression levels of (a) EphB4 receptor and (b) ephrin-B2 ligand in 
individual human endometrium specimens were determined by real-time RT-PCR as 
indicated in section 4.2.4. Data were obtained as an average value from triplicate wells 
and normalised to the value of the internal control HPRT1 in each sample. Results are 
represented as fold changes relative to a normal endometrium specimen (patient sample 
#1). 
 
4.3.2 EPHB4 and EFNB2 genes are commonly expressed in endometrial adenocarcinoma 
cell lines 
Immunohistochemical staining assays performed in previous studies have demonstrated a 
strongly increased epithelial expression of EphB4 proteins in the endometrial carcinomas 
comparing with an undetectable signal in the normal endometrium (Berclaz et al., 2003, 
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Alam et al., 2007). This phenomenon suggests that overexpression of EphB4 receptors in 
the endometrial epithelial cells might directly contribute to the tumorigenesis in human 
endometrial cancer. To explore this theory, expression of EphB4 receptor in several 
human endometrial epithelial cell lines modelled in 2D monolayers versus 3D MCSs were 
investigated.  
Real-time RT-PCR results showed variable mRNA expression levels of endogenous 
EPHB4 and EFNB2 in four different endometrial epithelial cell lines, with the highest level 
of EPHB4 and EFNB2 expression detected in the moderately differentiated HEC-1B cell 
line. In addition, endometrial epithelial cells in 3D MCSs showed significantly different 
levels of EPHB4 or EFNB2 transcript expressions compared to corresponding 2D controls 
(P<0.001), except for the Ishikawa cell line (Figure 4.2a and 4.2b).  
Likewise, variations were present in the endogenous EphB4 protein levels amongst 
different endometrial cell lines despite that it was commonly expressed in the four cell lines 
analysed (Figure 4.2c). The non-malignant E6/E7 cell line and poorly-differentiated KLE 
cancer cell line express relatively low levels of EphB4 protein; while much higher 
expression levels of EphB4 protein were detected in the well-differentiated Ishikawa cell 
line and the moderately-differentiated HEC-1B cell line. Moreover, EphB4 protein 
expression was increased in the 3D MCSs compared to their 2D counterparts, except that 
a slight decrease was observed in the KLE cell line. The most remarkable upregulation of 
endogenous EphB4 proteins were noted in the reconstructed 3D architecture of the 
Ishikawa and HEC-1B cell lines (P<0.01) (Figure 4.2d).  
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Figure 4.2 Expression of EphB4 and ephrin-B2 in a panel of human endometrial 
epithelial cell lines detected by RT-PCR and Western blotting 
Relative mRNA expression levels of (a) EPHB4 and (b) EFNB2 in the E6/E7, Ishikawa, 
HEC-1B and KLE cell lines from 2D and 3D cultures were determined by real-time RT-
PCR as indicated in section 4.2.4. Data were collected from four biological replicates 
analysed in technical triplicate. All specific transcript levels were normalised to HPRT1 
levels in each sample. (c) Representative Western blot for total EphB4 (~ 120 KDa) in 
whole cell lysates of above endometrial epithelial cell lines from 2D and 3D cultures. β-
Tubulin (~ 50 KDa) served as a loading control. The presented blot contains samples of an 
irrelevant cell line “GK-ISH” (2D and 3D) which however are excluded in the following data 
analysis. MCF-7 and MDA-MB-231 cell lines were used as positive controls. (d) Total 
EphB4 protein levels in the cell lines were quantified based on densitometry analysis 
results from three independent Western blots. The E6/E7 cells grown in 2D monolayers 
were used as the calibrator sample for multiple comparisons. Quantification results 
presented in these graphs are expressed as fold changes relative to the mRNA or protein 
expression levels in the calibrator sample. Unpaired two-tailed Student’s t-test was used 
for the comparison between paired 2D and 3D cell samples (**P<0.01, ***P<0.001, 
****P<0.0001). 
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4.3.3 EphB4 receptor kinase is poorly activated in endometrial cancer cells  
Surprisingly, despite the substantial levels of endogenous EphB4 expression in the 
endometrial adenocarcinoma cell lines, minimal tyrosine phosphorylation of EphB4 was 
found in these cancer cell lines (below 0.15 pg per µg of lysates) suggesting that the 
EphB4 receptor kinase is mostly not activated by the coexpressed ephrin-B2 ligand in 
endometrial cancer cells. Interestingly, a clear decline was further observed in 3D MCSs of 
the three endometrial cancer cell lines compared to their 2D counterparts. Conversely, 
with the non-malignant E6/E7 cell line, tyrosine-phosphorylated EphB4 levels were slightly 
increased in 3D MCSs compared to 2D monolayers (Figure 4.3).  
 
 
Figure 4.3 Basal levels of EphB4 tyrosine phosphorylation in a range of human 
endometrial epithelial cell lines determined by ELISA assays   
Phospho-EphB4 levels (pg per µg protein) in the 2D monolayers and 3D MCSs of E6/E7, 
Ishikawa, HEC-1B and KLE cell lines were determined by the human phospho-EphB4 
ELISA assay as described in section 4.2.6. Data were collected from two independent 
biological replicates analysed in technical duplicate.  
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4.3.4 Chimeric ephrin-B2/Fc stimulation increases activation of EphB4 receptor kinase in 
endometrial cancer cells  
To determine whether endogenous EphB4 receptors retain their kinase function in 
endometrial adenocarcinoma cells, Ishikawa cells were stimulated with clustered chimeric 
ligand ephrin-B2/Fc. A dramatic increase in the tyrosine phosphorylation of EphB4 was 
observed upon ligand binding in both 2D monolayers and 3D MCSs of Ishikawa cells 
(P<0.0001, Figure 4.4), which suggested that endogenous EphB4 receptor kinases in 
Ishikawa cells were activated in response to exogenous ephrin-B2 ligand. Hence, our data 
imply that kinase function of the EphB4 receptor might be preserved in endometrial 
adenocarcinoma cells which could be induced following ligand stimulation. 
In addition, NVP-BHG712 has been indicated as a potent inhibitor of EphB4 kinase by 
blocking EphB4 autophosphorylation, and it can also inhibit some other Eph receptor 
kinases including EphA2, EphA3, EphB2 and EphB3  (Martiny-Baron et al., 2010). After a 
1 hour pre-incubation of Ishikawa cells with NVP-BHG712 prior to ephrin-B2/Fc stimulation, 
we did not observe any increase in tyrosine phosphorylation of EphB4 when the cells were 
grown in 2D monolayers. However, for Ishikawa MCSs modelled in the 3D poly-HEMA 
system, NVP-BHG712 blocked most but not all the activation sites of EphB4 tyrosine 
kinase, and an elevation was obtained in the level of EphB4 tyrosine phosphorylation 
following stimulation with ephrin-B2/Fc (P<0.05, Figure 4.4). 
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Figure 4.4 Effects of chimeric ligand ephrin-B2/Fc and EphB4 kinase inhibitor NVP-
BHG712 on the regulation of EphB4 kinase activity in Ishikawa endometrial 
adenocarcinoma cells  
Ishikawa cells were grown as (a) 2D monolayers and (b) 3D MCSs and treated with 3 
μg/ml clustered chimeric ligand ephrin-B2/Fc (“eB2/Fc”), or a potent EphB4 kinase inhibitor 
NVP-BHG712 (“712+Fc”; 100 nM, IC50= 25 nM (Martiny-Baron et al., 2010)), or both after 
pre-incubated with 100 nM NVP-BHG712 for 1 hour (“712+eB2/Fc”) as described in 
section 4.2.7. Cells treated with Fc only served as controls. Cell lysates were prepared 
immediately after incubation with above treatments for 20 minutes. Phospho-EphB4 levels 
(pg per µg protein) in the cell samples were determined by the human phospho-EphB4 
ELISA assay as described in section 4.2.6. Data were collected from two biological 
replicates analysed in technical duplicate. One-way ANOVA analysis followed by Turkey’s 
post-hoc test was used for comparison across different treatments (*P<0.05, 
****P<0.0001).  
 
4.3.5 Chimeric ephrin-B2/Fc stimulation attenuates growth of endometrial cancer cells 
Simultaneously, chimeric ephrin-B2/Fc ligand stimulation led to significant reduction in cell 
viability of Ishikawa cells (Figure 4.5c and 4.5d). No significant differences were found 
between the cell groups treated with PBS or Fc control in our earlier studies (data not 
shown). More profound suppression in the cell proliferation following ephrin-B2 stimulation 
was observed in 3D MCSs (Figure 4.5d, P<0.0001) as compared to 2D monolayers 
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(Figure 4.5c, P<0.001), which suggests a tumour suppressive effect of EphB4 kinases 
induced by EphB4/ephrin-B2 interaction. This is in agreement with previous findings in 
other types of cancer that forward signalling of ligand-dependent EphB4 kinases is 
detrimental to cancer cells (Noren and Pasquale, 2007, Rutkowski et al., 2012, Ferguson 
et al., 2013). 
Additionally, it has been demonstrated in our study that growth of Ishikawa cells in 3D 
MCSs significantly increased following the treatment with EphB4 kinase inhibitor NVP-
BHG712 at concentrations of 10 to 100 nM (P<0.01). A small increase of cell growth was 
also observed in 2D cultures which however did not show a significant effect. Meanwhile, 
Ishikawa cells in the 3D MCSs exhibited greater resistance to the cytotoxicity induced by 
10 μM NVP-BHG712 as compared to those cells grown in 2D (Figure 4.5a and 4.5b). 
Surprisingly, whilst the tyrosine kinase activity of EphB4 was blocked with 100 nM NVP-
BHG712, further stimulation with the chimeric ligand ephrin-B2/Fc for another 48 hours 
resulted in robust growth attenuation of Ishikawa cells in both 2D monolayers and 3D 
MCSs (Figure 4.5c and 4.5d, “712+Fc” versus “712+eB2/Fc”, P<0.001). These data 
indicate that ephrin-B2 ligand-induced reduction in the growth of Ishikawa cells in the 
presence of NVP-BHG712 is very likely to be independent of the kinase activity of EphB4 
receptor.  
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Figure 4.5 Effects of chimeric ligand ephrin-B2/Fc and EphB4 kinase inhibitor NVP-
BHG712 on cell proliferation in Ishikawa endometrial adenocarcinoma cells 
Cell viability was determined by the MTS assay in (a) 2D monolayers and (b) 3D MCSs of 
Ishikawa cells after incubation with various concentrations of NVP-BHG712 (a potent 
inhibitor of EphB4 kinases; 0 – 104 nM) for 48 hours as indicated in section 2.8. Ishikawa 
cells were grown as (c) 2D monolayers or (d) 3D MCSs and incubated with different 
treatments for 48 hours as described in section 4.2.7. Cells were treated with 3 μg/ml 
clustered chimeric ligand ephrin-B2/Fc (“eB2/Fc”), or 100 nM NVP-BHG712 (“712+Fc”), or 
both after pre-incubation with 100 nM NVP-BHG712 for 1 hour (“712+eB2/Fc”). Cell 
viability was then determined by the MTS assay as indicated in section 2.8. Cells treated 
with Fc only served as controls. Data presented in these graphs were collected from three 
biological replicates analysed in technical triplicate. Results are expressed as percentage 
(%) relative to cells in the control groups. One-way ANOVA analysis followed by Turkey’s 
post-hoc test was used for comparison across different treatments (**P<0.01, ***P<0.001, 
****P<0.0001).  
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4.3.6 Coexpression of multiple Eph receptors is identified in endometrial epithelial cells  
Results from above ligand stimulation experiments have prompted that other Eph 
receptors might be coexpressed with EphB4 in endometrial epithelial cells, which could 
potentially compete with EphB4 in binding interactions with ephrin-B2, such as EphA3, 
EphA4 and other EphBs (Pasquale, 2004, Pabbisetty et al., 2007). To test this theory, we 
examined the transcript profiles of multiple Eph receptors (EPHA3, EPHA4, EPHB1, 
EPHB2 and EPHB3) in different endometrial epithelial cell lines by using RT-PCR. Unlike 
EphB4 receptor and ephrin-B2 ligand transcripts which were found to be commonly 
expressed in all the endometrial epithelial cell lines analysed, we found that the other 
investigated Eph receptors seem to be preferentially expressed in specific cell lines and 
differentially distributed in 2D versus 3D cell models (Figure 4.6).  
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Figure 4.6 Representative ethidium bromide stained agarose gels showing RT-PCR 
products of the expected size for multiple Eph receptors in various human 
endometrial epithelial cell lines  
The E6/E7, Ishikawa, HEC-1B and KLE endometrial epithelial cell lines were cultured as 
2D monolayers on plastic and 3D MCSs on poly-HEMA hydrogel, respectively. Gene 
transcripts of EPHA3, EPHA4, EPHB1, EPHB2 and EPHB3 as well as the housekeeping 
gene HPRT1 in 2D and 3D cultured cell samples were detected by RT-PCR as described 
in section 4.2.4. The human breast cancer cell line MCF-7 was used as a positive control. 
Negative controls were performed by omitting cDNA template (no-RT control; no template 
control, NTC) in the PCR mixture. M= marker (GeneRuler™ 100bp DNA ladder; Thermo 
Scientific). 
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4.4 Discussion 
Previous work has indicated the overexpression of EphB4 receptors in human endometrial 
cancer cells (Takai et al., 2001, Berclaz et al., 2003, Alam et al., 2007), yet its prognostic 
value in endometrial cancer is still unclear. Berclaz and colleagues examined 102 
endometrioid adenocarcinomas and their results showed no significant correlations 
between EphB4 expression and a number of clinical and prognostic tumour characteristics 
including histological grade and clinical stage of tumour, myometrial invasion, oestrogen 
receptor expression, body mass index of patients and clinical outcomes (Berclaz et al., 
2003). Nonetheless, another two groups in Japan working on a smaller size of patient 
samples, 20 endometrioid adenocarcinomas (Takai et al., 2001) and 68 endometrioid 
adenocarcinomas (Alam et al., 2007), have demonstrated in their studies that both of 
EphB4 and ephrin-B2 expression levels significantly increased with clinical stages, 
dedifferentiation and myometrial invasion in human endometrial cancers. In our study, we 
screened a small number of endometrial adenocarcinoma specimens (8 cases of 
endometrioid histotype; 1 case of serous histotype) together with four normal endometrium 
specimens and two endometrial hyperplasia specimens by real-time RT-PCR. In 
agreement with previous findings, EPHB4 is overexpressed in all the nine human 
endometrial adenocarcinoma tissues compared to very little expression in the normal 
endometrium tissues, whereas EFNB2 expression is not consistently increased in the 
tumour samples. Interestingly, the most dramatic increase in the transcript levels of 
EPHB4 and EFNB2 are identified in the two endometrial hyperplasia specimens and 
Grade 1 endometrioid adenocarcinomas specimens of earlier stages (less myometrial 
invasion). These results are similar to previous findings reported by Berclaz and 
colleagues (Berclaz et al., 2003). Since endometrial hyperplasia often precedes the 
development of endometrioid carcinoma and is generally considered a common precursor 
to endometrioid endometrial cancer (Ellenson et al., 2011), our findings suggest that 
EPHB4 overexpression might be an early event in endometrial tumorigenesis. However, 
due to the small sample size of patients included in this study, we are unable to draw a 
statistically meaningful conclusion. 
In addition, we have reported novel observation that EPHB4 and EFNB2 are coexpressed 
in several human endometrial epithelial cell lines. However, endogenous EphB4 receptor 
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kinases in the three examined endometrial adenocarcinoma cell lines are poorly tyrosine-
phosphorylated. Since activation of Eph receptor kinases is largely depend on 
phosphorylation of the tyrosine residues in their catalytic domain, extremely low basal 
levels of tyrosine-phosphorylated EphB4 receptor in endometrial cancer cells suggest that 
kinase activity of endogenous EphB4 receptor in these cells might be deficient. 
Furthermore, stimulation of Ishikawa cells with chimeric ligand ephrin-B2/Fc successfully 
activated the EphB4 receptor kinase by inducing a considerable increase in the tyrosine 
phosphorylation levels, suggesting that the EphB4 kinase in Ishikawa cancer cells are not 
constitutively inactivated but are indeed functional, retaining its kinase function and ligand-
responsive. It has been well acknowledged that trans-interactions between membrane-
bound EphB4 receptors and ephrin-B2 ligands normally occur at the sites of cell-cell 
contact (Davis et al., 1994). Thus, taken together, these results have suggested an 
aberrant expression pattern of the EphB4 receptor in human endometrial cancer cells such 
that the EphB4 receptor kinase is poorly activated by the coexpressed ephrin-B2 ligand, 
which further suggested that EphB4/ephrin-B2 signalling axis in these cells might be 
deregulated.  
Notably, variations are present in both mRNA and protein expression levels of EphB4 
across a range of different endometrial epithelial cell lines, which is attributed to the 
intrinsic differences in the genetic backgrounds and biological properties of each individual 
cell lines. Moreover, 3D MCS cell models and their 2D counterparts exhibited differential 
levels of EphB4 and ephrin-B2 expression. Thus, it is possible that cellular organisation 
such as the cell-cell contacts and the membrane structures might have a great impact on 
the expression and distribution patterns of EphB4 receptors and ephrin-B2 ligands in 
endometrial epithelial cells. Furthermore, our results indicated an inconsistency between 
mRNA and protein expression levels of EphB4 in Ishikawa and HEC-1B cell lines, 
indicating that expression of EphB4 tyrosine kinase might be regulated through post-
transcriptional and post-translational mechanisms in endometrial cancer cells. 
Intriguingly, there is also evidence in our current results showing that other family 
members of Eph receptors might be involved in regulating EphB4 signalling functions. 
Stimulation of Ishikawa cells with chimeric ephrin-B2/Fc ligand showed an inhibitory effect 
on cell growth suggesting a tumour-suppressing function of ligand-induced EphB4 kinase 
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signalling. Additionally, the EphB4 kinase inhibitor NVP-BHG712 (10 to 100 nM) alone 
increased Ishikawa cell proliferation, particularly in 3D MCSs, which we hypothesise is 
partly due to counteracting the anti-proliferative effect of endogenous EphB4 kinase 
activity. Strikingly, while the kinase activity of the EphB4 receptor was blocked, stimulation 
with ephrin-B2/Fc significantly reduced Ishikawa cell viability in both 2D and 3D models 
raising the likelihood that other coexpressed Eph receptor members also bind to ephrin-B2 
and coregulate EphB4 signalling activities through a crosstalk network. Indeed, we have 
found that genes of multiple Eph receptors that could potentially bind ephrin-B2 are 
expressed in the examined endometrial epithelial cell lines with variations detected across 
different cell lines and model systems.  
In summary, in this chapter we demonstrate that ligand-dependent EphB4 kinase activity 
elicits a tumour-suppressing response in endometrial cancer cells by preventing cell 
growth. However, endogenous EphB4 tyrosine kinase is found to be poorly activated in 
endometrial cancer cells suggesting that EphB4 forward signalling in this context is likely 
to be independent of its kinase activity. Therefore, we postulated that kinase-independent 
EphB4 forward signalling might exert a tumour-promoting role and contribute to 
endometrial cancer cell progression.  
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Chapter 5    Insights into the kinase-independent 
functions of EphB4 in human endometrial cancer 
cells  
5.1 Introduction 
Eph receptor tyrosine kinases (Ephs) and their ephrin ligands have been initially 
acknowledged for their well-defined developmental functions, particularly in the modulation 
of cell adhesion and segregation that leads to tissue patterning (Arvanitis and Davy, 2008, 
Pitulescu and Adams, 2010, Nievergall et al., 2012, Batlle and Wilkinson, 2012, Poliakov 
et al., 2004). More recently, accumulating evidence also implicates the crucial roles of 
Ephs and ephrins in orchestrating the physiology of adult tissues under normal and 
pathological conditions such as oncogenesis (Merlos-Suarez and Batlle, 2008, Janes et al., 
2008, Batlle and Wilkinson, 2012, Poliakov et al., 2004). EphB4 is one of the Eph 
members that have attracted by far the greatest interest in exploring their potential as 
therapeutic targets for human cancers (Boyd et al., 2014, Lisle et al., 2013). Nevertheless, 
the multifaceted role of EphB4 in tumorigenesis has been documented as either tumour-
promoting or tumour-suppressing or even both in the same type of cancer (Noren and 
Pasquale, 2007, Vaught et al., 2008, Kaenel et al., 2012, Boyd et al., 2014), indicating its 
function is highly context-dependent. These great disparities could be attributed to the 
complex nature of Eph receptor signalling owing to a large number of possible Eph-ephrin 
bi-directional interactions, combined signalling by other coexpressed Ephs and crosstalk 
with other receptor systems and cytoplasmic signalling molecules (Lisabeth et al., 2013, 
Pitulescu and Adams, 2010, Arvanitis and Davy, 2008, Boyd et al., 2014). Our previous 
work described in Chapter 4 has suggested a tumour suppressive role for EphB4 kinase-
dependent activities in human endometrial cancer cells. It has been reported that 
overexpression of EphB4 receptor with very low kinase signalling activity is commonly 
accompanied with low or lost expression of ephrin-B2 in human cancer cells (Noren and 
Pasquale, 2007, Lisle et al., 2013). Differences in the local levels of Eph-ephrin 
interactions often lead to distinct biological consequences (Hansen et al., 2004). Motivated 
by these findings, here we hypothesised that a disruption of EphB4/ephrin-B2 signalling 
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complexes, such as an alteration in the ratio of EphB4 and ephrin-B2 contents, might be 
responsible for the progression of endometrial cancer cells. In this regard, we continued to 
explore the biological effects of EphB4 – presumably kinase-independent roles based on 
its low tyrosine phosphorylation status and the fact that ephrin-B2 stimulation is anti-
proliferative – in human endometrial cancer cells by modifying the expression of EphB4 in 
these cells. 
5.2 Methods 
5.2.1 Generation of stable EphB4-knockdown endometrial cancer cell lines 
Lentiviral shRNA-mediated EphB4 gene knockdown has been successfully achieved in 
Ishikawa and HEC-1B human endometrial adenocarcinoma cell lines. Stable EphB4-
knockdown Ishikawa and HEC-1B cell lines were generated using two validated EPHB4-
shRNAs constructed in pLKO.1-puro (Catalog No.: TRCN0000001773; TRCN0000001774, 
Sigma-Aldrich) that target different exons of human EPHB4 (NM_004444) as described in 
section 2.13.1 (Figure 5.1). Cells transduced with a non-targeting lentiviral shRNA (NTC) 
served as negative controls (Bryant et al., 2010). The transduced Ishikawa and HEC-1B 
cell lines were maintained in phenol red-free DMEM/F12 (1:1) media supplemented with 
10% FBS and 2.5 μg/ml puromycin. For 3D modelling, above cell lines were grown on 
adherent-resistant poly-HEMA hydrogel as described in section 2.4.4.  
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Figure 5.1 Two validated EPHB4-shRNAs targeting different exons of human EPHB4 
gene 
(a) Short hairpin RNA-1 (Catalog No.: TRCN0000001773; Sigma-Aldrich) and (b) Short 
hairpin RNA-2 (Catalog No.: TRCN0000001774; Sigma-Aldrich) are targeting the 
sequence within the coding region of human EPHB4 (NM_004444.4) from nucleotide 2192 
to nucleotide 2212; and nucleotide 575 to nucleotide 595, respectively. Sequences of 
shRNA-1 and shRNA-2 and the respective targeted sequences are presented in a graphic 
format with the annotated features. Results were obtained from National Center for 
Biotechnology Information (NCBI) website www.ncbi.nlm.nih.gov by searching the 
Nucleotide Database.  
 
5.2.2 Generation of stable EphB4-overexpressing endometrial cancer cell lines 
Recombinant plasmid construct pIRES-B4 which carries the full-length coding sequence of 
human EPHB4 (NM_004444) and the empty vector pIRES-neo2 were kindly provided by 
Dr Sally-Anne Stephenson from QUT (Brisbane, Australia). Stable EphB4-overexpressing 
HEC-1B cell line was generated by transfected with pIRES-B4 construct as described in 
section 2.13.2. Cells transfected with pIRES-neo2 served as negative controls (Rutkowski 
et al., 2012). The transfected HEC-1B cell lines were maintained in phenol red-free 
DMEM/F12 (1:1) media supplemented with 10% FBS and 1 mg/ml Geneticin®. For 3D 
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modelling, above cell lines were grown on adherent-resistant poly-HEMA hydrogel as 
described in section 2.4.4.  
5.2.3 MTS assay 
The effect of EphB4 gene knockdown or EphB4 overexpression on cell growth were 
investigated in the transduced or transfected Ishikawa and HEC-1B cell lines outlined in 
sections 5.2.1 and 5.2.2. Cell growth was assessed in both 2D and 3D model systems. 
Cells were seeded into 96-well plates at a density of 2 × 103 cells/well and cell viability at 
different time points (4h, 24h, 48h and 72h after plating) were measured by the MTS assay 
as described in section 2.8. Results are expressed as percentage (%) relative to cell 
viability at the time point of 4h. Assessment of cell viability was started from 4 hours after 
plating (4h) which allowed the cells sufficient time to adhere. 
5.2.4 Soft-agar colony formation assay 
In vitro tumorigenicity of the transduced or transfected endometrial adenocarcinoma cell 
lines outlined in sections 5.2.1 and 5.2.2 were studied by clonogenic assays performed on 
a two-layer soft-agar system as described in section 2.9.  
5.2.5 Wound-healing migration assay 
The migration potential of the modified endometrial adenocarcinoma cell lines outlined in 
sections 5.2.1 and 5.2.2 were assessed by the scratch wound healing assay as described 
in section 2.10. Relative wound closure (%, value 0 means no migration) in each single 
well was determined by comparing the relative differences between the initial wound width 
and the wound width at the time point of 20 h when cell migration could be clearly seen. 
5.2.6 Western blotting 
Whole-cell lysates were prepared from 2D monolayers and 3D MCSs of the established 
endometrial adenocarcinoma cell lines outlined in sections 5.2.1 and 5.2.2 as described in 
section 2.7.1. Protein expressions of EphB4, phospho-FAK (p-FAK, Y397) and FAK, 
phospho-Paxillin (p-PXN, Y118) and PXN, phospho-Src (p-SRC, Y416) and SRC in a 
variety of cell samples were analysed by Western blotting as described in section 2.7.2. 
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After blotting for EphB4, membranes were stripped and reprobed with the β-Tubulin or 
GAPDH loading control antibodies. Membranes probed for the specific tyrosine-
phosphorylated proteins (p-FAK; p-PXN; p-SRC) were stripped and reprobed with the 
antibodies recognising the corresponding total proteins (FAK; PXN; SRC). Antibodies used 
for this study are listed in Table 2.1. Antibodies were reconstituted and diluted according to 
the supplier’s instructions.  
5.3 Results 
5.3.1 Knockdown of EphB4 attenuates the growth of endometrial cancer cells  
To determine the effect of EphB4 gene knockdown on cell survival in endometrial 
adenocarcinoma cells, stable knockdown of EphB4 expression was successfully achieved 
in the Ishikawa and HEC-1B cell lines using two independent and validated lentiviral 
EPHB4-shRNAs (shRNA-1 and shRNA-2). Potency of shRNA-1 and shRNA-2 mediated 
knockdown of EphB4 protein expression in comparison to the non-targeting shRNA control 
(NTC-shRNA) were confirmed by Western blotting. We found that in Ishikawa cells, 
shRNA-1 and shRNA-2 respectively knocked down EphB4 expression by 80% and 70% in 
2D monolayers (Figure 5.2a) and 70% and 65% in 3D MCSs (Figure 5.2d). In HEC-1B 
cells, shRNA-1 and shRNA-2 respectively downregulated EphB4 expression by 70% and 
55% in 2D monolayers (Figure 5.3a), and 90% and 85% in 3D MCSs (Figure 5.3d). 
Consequently, knockdown of EphB4 expression in Ishikawa and HEC-1B cancer cell lines 
dramatically decreased cell viability in 2D monolayers (P<0.0001, Figure 5.2b and 5.3b). 
Likewise, lower cell viability was also found in 3D MCSs of EphB4-knockdown Ishikawa 
and HEC-1B cancer cells in comparison to cells transduced with NTC-shRNA. However, 
attenuation of cell growth in 3D MCSs was found to be comparatively modest than 2D 
monolayers (Figure 5.2e and 5.3e). Additionally, clonogenic assays performed on soft agar 
also indicated that the number of larger-size colonies (larger than 100 µm in diameter) 
formed by Ishikawa and HEC-1B cells transduced with EPHB4-shRNAs was significantly 
reduced in comparison to cells transduced with NTC shRNA control (Figure 5.2h and 5.3h). 
Taken together, these results have clearly demonstrated that EphB4 gene knockdown 
results in a significant attenuation in the growth of endometrial cancer cells. 
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Figure 5.2 Lentiviral shRNA-mediated EphB4 knockdown attenuated the growth of 
Ishikawa endometrial adenocarcinoma cells  
Ishikawa cells were transduced with a non-targeting control shRNA (NTC) and two 
validated EPHB4-shRNAs (shRNA-1 and shRNA-2) as indicated in section 5.2.1. 
Representative Western blots showing EphB4 protein expressions in the cell samples 
obtained from (a) 2D monolayers and (d) 3D MCSs, respectively. The relative EphB4 
signal, normalised for β-Tubulin by densitometry analysis, is shown as a percentage (%) of 
NTC control beneath the Western blots. Subsequently, the effect of EPHB4 gene 
knockdown on the growth of Ishikawa cells in (b) 2D monolayers or (e) 3D MCSs was 
determined by the MTS assay as described in section 5.2.3. Data were collected from 
three biological replicates analysed in technical quadruplicate. Two-way ANOVA analysis 
with Bonferroni correction was used for comparisons between EphB4-knockdown cells and 
NTC-transduced cells (*P<0.05, ****P<0.0001). Micrographs showing representative 
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images taken from EphB4-knockdown or NTC-transduced Ishikawa cell lines after seeding 
at an identical cell number and culturing for 3 days in (c) 2D monolayers (original 
magnification of 10 ×, scale bar = 100 µm) or (f) 3D MCSs (original magnification of 20 ×, 
scale bar = 50 µm) by light microscopy. (g) Clonogenic assays were performed on a two-
layer soft-agar system as described in section 2.9. Micrographs showing representative 
images taken from EphB4-knockdown or NTC-transduced Ishikawa cell lines by light 
microscopy at an original magnification of 10 ×, scale bar = 100 µm. (h) Quantification of 
colony formation was performed by counting the number of colonies which were larger 
than 100 µm in diameter formed by each cell line. Data were collected from two biological 
replicates analysed in technical duplicate. One-way ANOVA analysis with Bonferroni 
correction was used for comparisons between EphB4-knockdown cells and NTC-
transduced cells (*P<0.05, ****P<0.0001). 
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Figure 5.3 Lentiviral shRNA-mediated EphB4 knockdown attenuated the growth of 
HEC-1B endometrial adenocarcinoma cells 
HEC-1B cells were transduced with a non-targeting control shRNA (NTC) and two 
validated EPHB4-shRNAs (shRNA-1 and shRNA-2) as indicated in section 5.2.1. 
Representative Western blots showing EphB4 protein expressions in the cell samples 
obtained from (a) 2D monolayers and (d) 3D MCSs, respectively. The relative EphB4 
signal, normalised for β-Tubulin by densitometry analysis, is shown as a percentage (%) of 
NTC control beneath the Western blots. Subsequently, the effect of EPHB4 gene 
knockdown on the growth of HEC-1B cells in (b) 2D monolayers or (e) 3D MCSs was 
determined by the MTS assay as described in section 5.2.3. Data were collected from 
three biological replicates analysed in technical quadruplicate. Two-way ANOVA analysis 
with Bonferroni correction was used for comparisons between EphB4-knockdown cells and 
NTC-transduced cells (*P<0.05, ****P<0.0001). Micrographs showing representative 
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images taken from EphB4-knockdown or NTC-transduced HEC-1B cell lines after seeding 
at an identical cell number and culturing for 3 days in (c) 2D monolayers (original 
magnification of 10 ×, scale bar = 100 µm) or (f) 3D MCSs (original magnification of 20 ×, 
scale bar = 50 µm) by light microscopy. (g) Clonogenic assays were performed on a two-
layer soft-agar system as described in section 2.9. Micrographs showing representative 
images taken from EphB4-knockdown or NTC-transduced HEC-1B cell lines by light 
microscopy at an original magnification of 10 ×, scale bar = 100 µm. (h) Quantification of 
colony formation was performed by counting the number of colonies which were larger 
than 100 µm in diameter formed by each cell line. Data were collected from two biological 
replicates analysed in technical duplicate. One-way ANOVA analysis with Bonferroni 
correction was used for comparisons between EphB4-knockdown cells and NTC-
transduced cells (*P<0.05, ****P<0.0001). 
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5.3.2 Knockdown of EphB4 impairs the migration of endometrial cancer cells 
In addition to the assessment of cell growth, the effect of EphB4 gene knockdown on cell 
migration was also investigated in the EphB4-knockdown Ishikawa and HEC-1B cell lines. 
Scratch wound healing assays were performed to measure the collective cell migration in 
each single well every 1 hour up to 24 hours in a fully kinetic manner. Uniformed wound 
marks were generated at the same time on confluent monolayers of EphB4-knockdown 
cells or NTC-shRNA transduced cells. Quantitative data demonstrated that cell migration 
was greatly impaired in the EphB4-knockdown Ishikawa (Figure 5.4a) and HEC-1B cell 
lines (Figure 5.4b) (P<0.0001). Compared to the NTC control, shRNA-1 reduced cell 
migration in both cell lines by ~ 50% (P<0.0001), whereas shRNA-2 exerted an even 
greater suppressive effect on cell migration by ~ 70% in the Ishikawa cell line (P<0.0001). 
HEC-1B cells transduced with shRNA-2 were not able to form an endurable confluent 
monolayer during the wounding process and thus were not included in these assessments. 
In summary, these data indicate that knockdown of EphB4 largely impairs the migration of 
endometrial cancer cells. 
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Figure 5.4 Lentiviral shRNA-mediated EphB4 knockdown impaired collective cell 
migration in Ishikawa and HEC-1B endometrial adenocarcinoma cells 
Uniformed scratch wounds were made on the confluent monolayers formed by the EphB4-
knockdown or NTC-transduced (a) Ishikawa and (b) HEC-1B cell lines. Micrographs 
demonstrating representative images taken from these cell lines by the IncuCyte™ kinetic 
live cell imaging system (Essen BioScience) at an original magnification of 10 ×. Collective 
cell migration in each individual cell lines at the time point of 20 h after wounding was then 
quantified as described in section 2.10. Data were collected from two biological replicates 
analysed in technical quadruplicate. Results are expressed as percentage (%) relative to 
cell migration in the corresponding NTC-transduced cell lines. One-way ANOVA analysis 
with Bonferroni correction was used for the comparison between EphB4-knockdown cells 
and the corresponding NTC-transduced cells (****P<0.0001).  
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5.3.3 Overexpression of EphB4 augments the growth and migration of endometrial cancer 
cells 
In order to generate additional data supporting the tumour promotive role of EphB4 
receptors in human endometrial cancer cells, EphB4 was overexpressed in HEC-1B 
endometrial cancer cells to assess whether it exhibited a reverse effect on the regulation 
of endometrial cancer cell phenotype. Stable overexpression of EphB4 was established in 
the HEC-1B cell line (HEC-1BEPHB4) in which EphB4 protein expression was increased by 
folds as compared to the control cells that were transfected with the empty vector (HEC-
1BEmV) (Figure 5.5, a and d).  
 
Interestingly, HEC-1BEPHB4 cancer cells seemed to develope a more aggressive phenotype 
(Figure 5.5 and 5.6). Compared to the HEC-1BEmV cells, cell viability in the HEC-1BEPHB4 
cells was significantly increased in 2D monolayers (Figure 5.5b, P<0.05). This 
phenomenon was even more evident in the 3D MCSs models (Figure 5.5e, P<0.0001). 
Additionally, overexpression of EphB4 greatly promoted colony formation on soft agar as 
indicated by a dramatic elevation in the number of colonies with larger sizes (in excess of 
100 μm in diameter) (Figure 5.5h, P<0.001). Furthermore, wound healing assays 
demonstrated a 30 – 40% increase in the collective cell migration in HEC-1BEPHB4 cells 
compared to HEC-1BEmV cells (Figure 5.6, P<0.01). Overall, our data showed a strong 
augmentation of cell growth and migration in the EphB4-overexpressing HEC-1B (HEC-
1BEPHB4) cancer cells. Accordingly, these results suggest that overexpression of EphB4 
receptors may contribute to the progression of endometrial cancer cells by favouring cell 
growth and migration, and thus is considered as oncogenic in the endometrial epithelial 
cell niches.  
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Figure 5.5 Forcing EphB4 overexpression augmented the growth of HEC-1B 
endometrial adenocarcinoma cells  
HEC-1B cells were transfected with the empty vector pIRES-neo2 (HEC-1BEmV, “EmV”) 
and pIRES-B4 construct containing full-length coding sequence of human EPHB4 (HEC-
1BEPHB4, “B4”) as indicated in section 5.2.2. Representative Western blots showing EphB4 
protein expression in the cell samples obtained from (a) 2D monolayers and (d) 3D MCSs, 
respectively. The relative EphB4 signal, normalised for β-Tubulin by densitometry analysis, 
is shown as a percentage (%) of EmV control beneath the Western blots. Subsequently, 
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the effect of EphB4 gene overexpression on the growth of HEC-1B cells in (b) 2D 
monolayers and (e) 3D MCSs were determined by the MTS assay as described in section 
5.2.3. Data were collected from three biological replicates analysed in technical 
quadruplicate. Two-way ANOVA analysis with Bonferroni correction was used for the 
comparison between HEC-1BEPHB4 cells and HEC-1BEmV cells (*P<0.05, ****P<0.0001). 
Micrographs showing representative images taken from HEC-1BEPHB4 or HEC-1BEmV cell 
line after seeding at an identical cell number and culturing for 3 days in (c) 2D monolayers 
(original magnification of 10 ×, scale bar = 100 µm) and (f) 3D MCSs (original 
magnification of 20 ×, scale bar = 50 µm) by light microscopy. (g) Clonogenic assays were 
performed on a two-layer soft-agar system as described in section 2.9. Micrographs 
showing representative images taken from HEC-1BEPHB4 or HEC-1BEmV cell line by light 
microscopy at an original magnification of 10 ×, scale bar = 100 µm. (h) Quantification of 
colony formation was performed by counting the number of colonies which were larger 
than 100 µm in diameter formed by each cell line. Data were collected from two biological 
replicates analysed in technical triplicate. Unpaired two-tailed Student’s t-test was used for 
the comparison between HEC-1BEPHB4 cells and HEC-1BEmV cells (***P<0.001). 
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Figure 5.6 Forcing EphB4 overexpression facilitated collective cell migration in 
HEC-1B endometrial adenocarcinoma cells  
Uniformed scratch wounds were made on the confluent monolayers formed by the EphB4-
overexpressing (HEC-1BEPHB4, “B4”) or empty vector-transfected (HEC-1BEmV, “EmV”) 
HEC-1B cell line. Micrographs demonstrating representative images taken from these two 
cell lines by the IncuCyte™ kinetic live cell imaging system (Essen BioScience) at an 
original magnification of 10 ×. Collective cell migration in each individual cell lines at the 
time point of 20 h after wounding was then quantified as described in section 2.10. Data 
were collected from two biological replicates analysed in technical quadruplicate. Results 
are expressed as percentage (%) relative to the cell migration in the HEC-1BEmV cell line. 
Unpaired two-tailed Student’s t-test was used for the comparison between HEC-1BEPHB4 
cells and HEC-1BEmV cells (**P<0.01).  
 
5.3.4 EphB4 modulates endometrial cancer cell survival and motility possibly involving the 
regulation of focal adhesion signalling complexes 
Studies show that a group of subcellular structures called focal adhesions lie at the 
convergence of integrin-mediated cell-ECM signalling (Wu, 2007, Wozniak et al., 2004). 
Focal adhesion proteins physically and functionally interact to facilitate cancer progression 
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by regulating oncogenic processes such as cell motility, survival, proliferation, 
invasiveness, and angiogenesis (McLean et al., 2005, Sachdev et al., 2009, Nagano et al., 
2012). Thus, we speculated that EphB4 is likely to modulate the survival and motility of 
endometrial cancer cells through a downstream regulation of focal adhesion signalling 
complexes. In order to find the evidence supporting this hypothesis, expression and 
activity of three key focal adhesion components including focal adhesion kinase (FAK), 
adaptor protein paxillin and Src tyrosine kinase were investigated in the established 
EphB4-knockdown and EphB4-overexpressing endometrial cancer cell lines.  
Importantly, FAK, paxillin and Src focal adhesion proteins are tyrosine kinases and each 
contains a number of tyrosine residues that could be potentially phosphorylated upon 
activation and generate distinct signals (Nagano et al., 2012, Wozniak et al., 2004). 
Present knowledge obtained from 2D cell models shows that phosphorylation of FAK at 
the autophosphorylation site Tyr397 generates a high affinity binding site for recruiting 
SH2-domain-containing proteins such as Src family kinases, PI-3 kinase and p130Cas to 
the sites of focal adhesions (Cobb et al., 1994, Schaller et al., 1994, Chen and Guan, 1994, 
Zhang et al., 1999, Parsons et al., 2000). Upon binding to Tyr397-phosphorylated FAK, 
Src is activated at Tyr416 in its kinase domain which further increases the activities of FAK 
and adaptor proteins such as p130Cas and paxillin (Schlaepfer and Hunter, 1996, Frame 
et al., 2002, Thomas and Brugge, 1997). Both FAK and Src can stimulate the 
phosphorylation of paxillin at the site of Tyr118 which then provides a docking site for 
recruiting various signalling molecules to the focal adhesion complexes leading to changes 
in cell morphology and behaviour (Bellis et al., 1997, Wozniak et al., 2004, Vadlamudi et 
al., 2002). In this study, we employed a series of well-characterised antibodies that 
recognise phosphorylated forms of FAK, paxillin and Src at their specific tyrosine residues. 
Our results demonstrated that phosphorylation status of above focal adhesion proteins 
were differentially regulated by EphB4 amongst different cell lines as well as between 2D 
and 3D cell models (Figure 5.7).  
In 2D monolayers, Tyr397-phosphorylated FAK levels were decreased in EphB4-
knockdown Ishikawa cells suggesting that FAK autophosphorylation and kinase activation 
are likely inhibited by EphB4 knockdown, whereas no changes were noticed in the 
phosphorylation levels of paxillin-Tyr118 and Src-Tyr416 (Figure 5.7a). Surprisingly, we 
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observed a distinct regulation pattern of these FA kinases in 3D culture where 
phosphorylation of FAK on Tyr397 seemed to be abolished in Ishikawa cells transduced 
with NTC-shRNA but was found to be increased in EphB4-knockdown Ishikawa cell lines. 
Moreover, we found a clear reduction in paxillin-Tyr118 phosphorylation but not in Src-
Tyr416 phosphorylation following EphB4 knockdown in Ishikawa cells (Figure 5.7d).  
Intriguingly, FAK-Tyr397 phosphorylation was hardly detected in HEC-1B cells transduced 
with EPHB4-shRNAs and NTC-shRNA, regardless of 2D or 3D culture models (Figure 
5.7b and 5.7e). In 2D monolayers, we found a slight increase in paxillin-Tyr118 
phosphorylation in EphB4-knockdown HEC-1B cell lines compared with cells transduced 
with NTC-shRNA, whereas very subtle change was seen in Src-Tyr416 phosphorylation 
(Figure 5.7b). In contrast, an obvious decrease in Src-Tyr416 phosphorylation was 
indicated in EphB4-knockdown HEC-1B cell lines cultured in 3D (Figure 5.7e). On the 
contrary, we observed a strong increase in FAK-Tyr397 phosphorylation in HEC-1BEPHB4 
cells compared to HEC-1BEmV cells, while increase in phosphorylation of paxillin-Tyr118 
and Src-Tyr416 were not detectable (Figure 5.7c). These results were obtained from two 
independent biological replicates, with representative results presented. Due to the limited 
amount of time and antibodies left in this project, we did not pursue further analyses. 
However, additional biological replicates are required to confirm the existing results. 
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Figure 5.7 Representative Western blots showing EphB4-mediated regulation of 
focal adhesion tyrosine kinases activities in Ishikawa and HEC-1B endometrial 
adenocarcinoma cells  
Stable EphB4 knockdown and EphB4 overexpression were established in Ishikawa and 
HEC-1B cell lines as described in section 5.2.1 and 5.2.2, respectively. Protein expression 
of EphB4, p-FAK (Tyr397)/FAK, p-PXN (Tyr118)/PXN, p-SRC (Tyr416)/SRC and the 
loading control GAPDH were detected by Western blotting as indicated in section 5.2.6. 
Identities of the samples presented in above graphs are as follows: (a) EphB4-knockdown 
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and NTC-transduced Ishikawa cell lines in 2D monolayers; (b) EphB4-knockdown and 
NTC-transduced HEC-1B cell lines in 2D monolayers; (c) EphB4-overexpressing and 
EmV-transfected HEC-1B cell lines in 2D monolayers; (d) EphB4-knockdown and NTC-
transduced Ishikawa cell lines in 3D MCSs; (e) EphB4-knockdown and NTC-transduced 
HEC-1B cell lines in 3D MCSs. NTC: cell line transduced with a non-targeting shRNA 
lentiviral construct which served as a control for EphB4-knockdown cell lines; shRNA-1: 
EphB4-knockdown cell line transduced with EPHB4-shRNA-1 lentiviral construct; shRNA-2: 
EphB4-knockdown cell line transduced with EPHB4-shRNA-2 lentiviral construct; EmV: 
cell line transfected with the empty vector pIRES-neo2 (HEC-1BEmV); B4: EphB4-
overexpressing cell line transfected with pIRES-B4 (HEC-1BEPHB4). FAK: focal adhesion 
kinase; PXN: paxillin tyrosine kinase; SRC: Src tyrosine kinase. 
 
5.4 Discussion 
EphB4 has been implicated to play a major role in regulating cancer cell survival and 
motility during the development of a variety of human malignancies (Wang, 2011, 
Pasquale, 2005, Campbell and Robbins, 2008, Perez White and Getsios, 2014). 
Previously in this study, we have demonstrated that overexpression of EphB4 receptor 
lacking the kinase activity seems to contribute to the progression of endometrial cancer 
cells. Here, to further assess the phenotypic effects of EphB4 activities on endometrial 
cancer cells, we performed both knockdown and overexpression of human EPHB4 in 
different endometrial cancer cell lines. Our findings suggest that overexpression of EphB4 
in HEC-1B cells propelled endometrial cancer cells to progress to a more aggressive 
phenotype by facilitating cell survival and motility, which is highly possible to be 
independent of endogenous ligand stimulation and mediated through a kinase-
independent mechanism given the very low kinase activity in the wild-type HEC-1B cells. 
Nevertheless, this biological effect could be opposed through the genetic ablation of 
EphB4 since a reduction in cell proliferation and migration was seen by knockdown of 
EphB4 expression in HEC-1B cells. In this study, shRNA-1 and shRNA-2 targeting 
different exons of human EPHB4 both potently knocked down the expression of EphB4 in 
Ishikawa and HEC-1B cancer cell lines. One possible caveat is that shRNA-2 delivered a 
relatively lower EphB4-knockdown potency yet induced a greater global inhibition of cell 
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survival and motility as compared to shRNA-1 and it is therefore possible that shRNA-2 
may have additional off-target effects. To confirm the on-target effects of EPHB4 gene 
knockdown obtained in our study and minimise the potential off-target effects of the 
currently used EPHB4-shRNAs, use of two additional independent and validated shRNAs 
targeting different exons of EPHB4 gene could be engaged in a future study to validate our 
present data.  
In addition, our data suggest that several focal adhesion signalling components are 
possibly regulated downstream of EphB4 to modulate endometrial cancer cell survival and 
motility. In HEC-1B cells transfected with full-length EPHB4 gene, we observed a profound 
increase of FAK autophosphorylation together with an upregulation of Src and paxillin 
kinase activities suggesting that these focal adhesion components formed signalling 
complexes through sequential activations which were induced by overexpression of EphB4. 
It has been reported that FAK and Src kinases can cooperate to form signalling complexes 
and phosphorylate adaptor protein paxillin which further promote cell survival and motility 
through a wide net of downstream signals in 2D cell models (Brown et al., 2005, Kawauchi, 
2012, Schlaepfer et al., 2004, Sachdev et al., 2009). This is consistent with the phenotype 
we observed in HEC-1BEPHB4 cancer cells which showed higher migratory potential and 
enhanced anchorage-independent growth. On the other hand, FAK autophosphorylation 
was greatly inhibited in EphB4-knockdown Ishikawa cells but not in EphB4-knockdown 
HEC-1B cells. Since the regulation of focal adhesions is highly dynamic and cross-linked 
to an array of signalling events, a simple change in FAK phosphorylation at Tyr397 can be 
expected to have profound changes in the downstream signalling pathways, which 
ultimately influences cell behaviour and phenotype (Wozniak et al., 2004). Thus, it is 
possible that signalling events downstream of EphB4 are different in Ishikawa and HEC-1B 
cell lines, in which autophosphorylation of FAK might be redundant. Future experiments 
performed in additional endometrial cancer cell lines with high levels of EphB4 expression 
and constitutively activated FAK will help to verify this theory. However, it is also possible 
that disparities in the genetic backgrounds of individual cell lines, which is independent of 
EphB4 expression, might contribute to the different levels of endogenous FAK kinase 
activity. Since other Eph receptors such as EphA2, EphB2 and EphB3 have also been 
implicated to influence cell-cell contacts and regulate cell survival and migration (Chiu et 
al., 2009, Boyd et al., 2014); such a discrepancy observed between Ishikawa and HEC-1B 
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cell lines might be due to the differences in the global Eph receptors expression profile. 
Thus, we propose that the biological properties of endometrial cancer cells are largely 
determined by the balance of total Eph signalling activities.  
Intriguingly, we also found that EphB4 differentially regulates signalling from the focal 
adhesion complexes in 2D monolayers versus 3D MCSs. This is in line with the findings 
demonstrated in some pioneering studies that focal adhesions formed in vivo or in 3D 
environments are fundamentally different from their 2D counterparts (Wozniak et al., 2004, 
Nagano et al., 2012, Cukierman et al., 2001). Here we examined the phosphorylation on 
specific tyrosine residues of FAK (Tyr397), paxillin (Tyr118) and Src (Tyr416) that were 
modulated by EphB4 expression, however phosphorylated on some other tyrosine 
residues of these focal adhesion protein kinases could be potentially involved. For 
example, EphB2 suppression using siRNA significantly reduced cholangiocarcinoma cell 
migration by decreasing the phosphorylation of FAK on Tyr576 and Tyr 577 (Khansaard et 
al., 2014). Further studies utilising advanced imaging technologies, such as using 
fluorescent-tagged antibodies recognising specific phosphorylation residues of focal 
adhesion proteins followed by confocal imaging to study their temporal and spatial  
distributions in 2D versus 3D cellular environments, might help us to better understand the 
dynamic compositions and signalling activities of focal adhesions involved in the 
downstream regulation of EphB4 signalling during the progression of endometrial cancer 
cells.  
Collectively, our results shown in this chapter provide good evidence to support that 
overexpression EphB4 promotes cell survival and motility in a kinase-independent manner, 
probably involving the downstream upregulation of FAK, paxillin and Src focal adhesion 
signalling in endometrial cancer cells. Therefore, we conclude that EphB4 forward 
signalling independent of its kinase activity plays a tumour-promoting role in the 
progression of human endometrial cancer cells. 
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Chapter 6    General Discussion and Future 
Directions 
Endometrial cancer is the most common malignancy of the female genital tract, and patient 
survival from advanced stages or recurrence of this disease still remains a challenge 
(Murali et al., 2014, Amant et al., 2005). The need for identification of novel molecular 
targets to develop more effective therapeutic strategies has been emphasised. For many 
years, EphB4/ephrin-B2 signalling system has been studied in a developmental context; 
however, recent findings clearly highlighted its involvement in adult diseases, such as 
cancer (Merlos-Suarez and Batlle, 2008, Campbell and Robbins, 2008, Kaenel et al., 2012, 
Falivelli et al., 2013). The EphB4 receptor has been unveiled to play a crucial role in the 
control of a multitude of cell functions and behaviours, which brings it to light as a potential 
candidate for targeted cancer therapy (Lisle et al., 2013, Boyd et al., 2014), though the 
exact mechanistic basis for these processes are not fully understood. The objective of this 
study was to explore the involvement of the EphB4/ephrin-B2 system in regulating cell 
survival and motility which can contribute to the tumour progression in endometrial cancer. 
This thesis presents the key findings of current study: 1) deregulated expression of EPHB4 
and EFNB2 genes is present in human endometrial tumour tissues and cancer cell lines; 2) 
evaluation of EphB4 biology in 3D multicellular spheroids shows several differences in 
comparison to traditional 2D monolayers; 3) ephrin-B2 ligand-induced EphB4 kinase 
activity has a tumour-suppressing effect on the survival of endometrial cancer cells in vitro; 
4) kinase-independent EphB4 forward signalling plays a tumour-promoting role in the 
progression of endometrial cancer by favouring cancer cell survival and migration, perhaps 
in part, through a regulation of downstream focal adhesion signalling cascades. 
6.1 Use of multicellular spheroids (MCSs) as 3D in vitro models  
The 3D MCSs are well recognised cellular models that are more representative of living 
tissues than traditional 2D monolayers due to their physiological relevance (Pampaloni et 
al., 2007, Kim, 2005, Yamada and Cukierman, 2007). In this study, we used MCSs 
generated from single endometrial epithelial cells as 3D in vitro models. A number of 
modelling methods were tried and MCSs formed on adherent-resistant poly-HEMA 
hydrogel were established as a simple and affordable 3D model system. This part of work 
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has been described and discussed in Chapter 3. We found that endometrial cells grown in 
the poly-HEMA model system formed remarkably different structures from 2D monolayers 
by reconstructing the 3D architecture. Moreover, different endometrial adenocarcinoma 
cell lines developed distinctive phenotypes of MCSs in the 3D system, which are 
reminiscent of the in vivo equivalents of different grades (Figure 3.8). In addition to the 
distinctions in morphology, cells in 3D MCSs also displayed crucial differences in the 
biological properties as compared to cells in 2D monolayers. For example, cells in MCSs 
proliferated relatively slower than cells grown in 2D and exhibited differential responses to 
drug treatments (Figure 4.4 and 4.5). These results are expected attributed to the 
thickness of the MCS structures and a differential cell arrangement in the 3D architecture 
that cause the transportation limitations within the 3D environment, that is cells at different 
depths from the surface access various levels of oxygenation, nutrition, and drug toxicity or 
stimuli, while culture conditions are uniform for 2D monolayers. Notably, 3D MCSs also 
differ from their 2D counterparts in the expression of a series of genes and proteins as well 
as the possible signalling activities, such as EFNB2 and multiple Eph receptor genes 
including the EphB4 receptor (Figure 4.2, 4.3 and 4.6), and focal adhesion proteins FAK, 
Src and paxillin (Figure 5.7). Our results seem to be consistent with some earlier findings 
that the composition and function of cell-matrix adhesions are altered by the reconstructed 
3D architecture which is distinctive from what has been classically described in 2D cell 
models (Cukierman et al., 2001, Wozniak et al., 2004, Nagano et al., 2012). Combined 
together, these data suggest that 3D model systems hold a great promise for studying the 
complex roles of ephrin-B2/EphB4 system in a more physiologically representative 
environment and existing publications presenting data obtained from 2D model systems 
may not necessarily be true in the 3D setting.  
In a word, use of 3D in vitro cellular models in this study has provided us new insights into 
the role of EphB4 forward signalling in endometrial cancer cells. Nevertheless, this type of 
3D model system certainly has its experimental drawbacks. Firstly, cell-derived matrices in 
this system can have lower amounts of collagen, larger internal spaces, and less depth 
than mature tissue matrices (Yamada and Cukierman, 2007). Secondly, as a monotypic in 
vitro model system, it lacks the complex vasculature and stromal compartments that 
characterise tissues in vivo. This may be relevant given that the EphB4 extracellular 
domain can induce angiogenic responses by stimulating ephrin-B2 reverse signalling in 
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cultured endothelial cells and tumour xenografts (Noren and Pasquale, 2007). Therefore, 
future studies in animal models might be necessary for a systematic investigation of the in 
vivo roles of EphB4/ephrin-B2 signalling system involved in endometrial cancer. 
6.2 Kinase-dependent versus kinase-independent EphB4 forward signalling 
Although the consensus reached from current clinical findings is that the EphB4 receptor is 
overexpressed in the endometrial tumours compared to very little expression found in the 
normal endometrium, the biological significance of EphB4 expression in endometrial 
cancer is still unclear. In this study, we have added in new evidence to fill the knowledge 
gap with respect to in vitro functional studies of EphB4 and ephrin-B2 in endometrial 
cancer cells.  We examined the expression of EphB4/ephrin-B2 axis in a small number of 
human endometrial tissue specimens and epithelial cell lines and further characterised 
opposing roles of EphB4 forward signalling in endometrial cancer cells which are believed 
to be mediated through kinase-dependent and kinase-independent pathways, respectively. 
This part of work has been described and discussed in Chapter 4 and 5.  
We found that EPHB4 levels were increased in all the examined endometrial hyperplasia 
lesions and adenocarcinomas in comparison to the normal endometrium while increase of 
EFNB2 expression in these samples did not show a similar consistency (Figure 4.1). 
However, these data are insufficient to relate EphB4 and ephrin-B2 expression to clinical 
stage or tumour grade in endometrial cancer due to the small cohort of clinical samples. 
Therefore, further analysis of these two genes in a larger patient series is needed to 
identify clinical correlations and determine the possible scope of targeted therapies.  
We also add in new data on the expression profile of EphB4 and ephrin-B2 in a number of 
human endometrial cell lines. Coexpression of EPHB4 and EFNB2 while at varied levels 
was observed across the four endometrial cell lines analysed (Figure 4.2), which is 
presumably associated with inherent differences in their genetic background and cellular 
characteristics. Discrepancies seen between mRNA and protein levels of EphB4 in 
Ishikawa and HEC-1B cell lines indicate that EphB4 expression might be regulated at both 
post-transcriptional and post-translational levels. Despite the strong expression of EphB4 
proteins in endometrial cancer cells, extremely low levels of tyrosine phosphorylation were 
observed (Figure 4.3). These data suggest that endogenous EphB4 receptor kinases are 
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poorly activated at the basal level in endometrial cancer cells and very likely to signal 
independently of the coexpressed ephrin-B2 ligands. Intriguingly, stimulation with clustered 
chimeric ligand ephrin-B2/Fc demonstrates that the EphB4 receptor kinase in endometrial 
cancer cells is not constitutively inactivated but remains ligand-responsive. The ligand-
induced EphB4 kinase activity leads to an anti-proliferation effect on endometrial cancer 
cells (Figure 4.4 and 4.5), which is consistent with the observations in other cancer types 
showing that ligand-stimulated EphB4 kinase signalling is detrimental to tumour 
development (Xia et al., 2005b, Kumar et al., 2006, Noren et al., 2006, Rutkowski et al., 
2012, Dopeso et al., 2009), although a contradictory report exists in melanoma (Yang et 
al., 2006, Yang et al., 2010). Accordingly, we hypothesise that deregulated expression of 
the EphB4 receptor is present in endometrial cancer cells which results in the disruption of 
tumour suppressive EphB4/ephrin-B2 signalling and might further contribute to cancer 
pathogenesis.  
A possible mechanism could be that the ectopic expression of EphB4 and ephrin-B2 
mediates inappropriate signalling activities. For instance, cis interactions between 
coexpressed EphB4 and ephrin-B2 impair the anti-oncogenic activities of EphB4 kinase 
signalling that require trans interactions between EphB4 and ephrin-B2 expressed in 
neighbouring tumour cells. Alternatively, subcellular distributions of EphB4 and ephrin-B2 
might be aberrant in endometrial cancer cells. Mislocalisation of EphB4 from the cell 
surface to cytoplasm has been reported in breast (Wu et al., 2004) and prostate cancer 
cells (Lee et al., 2005). Strong EphB4 antigen signals were detected on the plasma 
membranes of epithelial cells in endometrial hyperplasia and tumour tissues by Berclaz 
and colleagues (Berclaz et al., 2003). Another group found strong and positive staining for 
ephrinB2 and EphB4 in the cytoplasm and cell membrane of cancer cells (Alam et al., 
2007). Additional studies taking advantage of the 3D cellular models and advanced 
confocal imaging technologies to detect the subcellular location of EphB4 and ephrin-B2 
using specific antibodies will help to corroborate this theory. While this study focused on 
the expression and potential roles of EphB4 receptor, it is likely that expression and 
signalling function of the ephrin-B2 ligand are also altered in endometrial cancer cells. 
Relevant functional studies were not further pursued due to the time constraints in this 
study.  
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Given the low levels of ephrin-B2 ligand-induced EphB4 kinase signalling in endometrial 
cancer cells, tumour-promoting functions of the EphB4 receptor are likely to be 
independent of autocrine- or paracrine- ephrin-B2 stimulation and also of its kinase activity. 
Here we provided two lines of evidence demonstrating an oncogenic role of kinase-
independent EphB4 forward signalling in regulating endometrial cancer cell growth and 
migration. First, shRNA-mediated EphB4 knockdown in two independent endometrial 
cancer cell lines markedly reduced cell growth in 2D and 3D MSCs, colony formation and 
migration (Figure 5.2, 5.3 and 5.4). Second, overexpression of wildtype EphB4 in one of 
these cell lines resulted in increased cell proliferation, clonogenicity and migration (Figure 
5.5 and 5.6). As cancer cells that adopt anchorage-independent growth on poly-HEMA 
exploit resistance to anoikis, a type of apoptosis induced upon cell detachment from 
extracellular matrix (Kozlova et al., 2001, Paoli et al., 2013, Goundiam et al., 2010), this 
data suggests that EphB4 overexpression provides resistance to anoikis. These results 
are in agreement with previous findings in breast (Kumar et al., 2006), prostate (Xia et al., 
2005b), lung (Ferguson et al., 2013), oesophageal (Hasina et al., 2013), bladder (Xia et 
al., 2006), ovarian (Kumar et al., 2007), thyroid (Xuqing et al., 2012), head and neck 
cancers (Masood et al., 2006) where downregulation of EphB4 by RNA interference 
reduced cancer cell survival, proliferation, colony formation, migration and invasion in 
monolayer cultures as well as tumour growth in xenograft models. Further investigation in 
this study has revealed that EphB4 might modulate endometrial cancer cell survival and 
motility, perhaps in part, through the downstream regulation of focal adhesion signalling 
complexes. To conclusively demonstrate that endogenous EphB4 receptor in endometrial 
cancer cells functions independent of endogenous ephrin-B2 ligand in a kinase-
independent manner, subsequent experiments may include comparing the biological 
effects already observed in EphB4-overexpressing HEC-1B cells to those obtained 
following stable transfection of a kinase-dead or kinase domain-truncated form of human 
EPHB4. If the oncogenic role of EphB4 was independent of its kinase activity we would 
expect similar promoting effects in cell survival and migration with these kinase activity-
depleted mutants. Otherwise, to block endogenous kinase-dependent ephrin-B2/EphB4 
signalling, cells could also be treated with kinase-null soluble EphB4/Fc that lacks the 
cytoplasmic portion and we could determine if the cytoplasmic domain mediates a 
separate kinase-independent function. We could also determine whether endogenous 
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ephrin-B2 functions to suppress tumorigenesis by assessing cell proliferation and 
migration following knockdown of EFNB2 or using a neutralising antibody that antagonises 
the binding of ephrin-B2 to EphB4. 
Interestingly, we found that treatment with a potent EphB4 kinase inhibitor NVP-BHG712 
alone elicited a growth-promoting response in Ishikawa cells, especially in 3D MCSs 
(Figure 4.5). This observation could be in consequence of blocking the anti-proliferative 
EphB4 kinase signalling, and could also be a balancing outcome between EphB4 and 
other cross-linked Eph signalling since NVP-BHG712 can also inhibit kinase activity of 
other Eph receptors such as EphA2, EphA3, EphB2 and EphB3 (Martiny-Baron et al., 
2010). The pan Eph inhibitor NVP-BHG712 was able to fully block the activation of EphB4 
tyrosine kinase in 2D but not in 3D culture of Ishikawa cells (Figure 4.4), which partially 
antagonised the anti-proliferation effect of stimulation with chimeric ephrin-B2/Fc ligand in 
3D models (Figure 4.5), raising the likelihood that ligand-dependent but kinase-
independent EphB4 signalling might be mediated through other binding partners of ephrin-
B2 and EphB4. Emerging evidence has indicated that Eph receptors are able to form 
heterodimers and lead to varied biological effects. For example, the kinase-deficient 
EphB6 receptor has been shown to undergo transphosphorylation upon stimulation with 
ephrin-B1 through a crosstalk with EphB1 receptor (Freywald et al., 2002). Another study 
implicates that cellular phenotypes may in part be attributed to a combinatorial expression 
of Eph receptors and heteromeric interactions among them (Fox and Kandpal, 2011). In 
other words, biological functions of individual Eph receptors in the cells need to be 
determined by an overview of the global Eph expression profile. Indeed, our preliminary 
data have demonstrated that multiple Eph receptors such as EPHA3, EPHA4, EPHB1, 
EPHB2 and EPHB3 are coexpressed with EPHB4 and EFNB2 in endometrial epithelial 
cells and differentially expressed in individual cell lines, which might participate in 
orchestrating the biological effects of EphB4 forward signalling. However, there is also 
strong evidence from a large number of preclinical studies with disease-specific genome 
profiling indicating that in many of the pathological conditions only a selective spectrum of 
Ephs or ephrins are driving the disease even if other family members are coexpressed in 
the same cells (Boyd et al., 2014). Other than EphB4, overexpression of EphA2 has been 
associated with aggressive phenotypic features and poor clinical outcome in endometrial 
cancer (Kamat et al., 2009). Further characterisation of crosstalk interactions between 
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EphB4 and other coexpressed Eph receptors will improve our understanding of the 
comprehensive EphB4 signalling mechanisms underlying its potential roles in the 
progression of endometrial cancer. 
6.3 Regulation of EphB4 forward signalling might shed light on EphB4-targeted 
therapeutics  
Our survey suggests that EphB4 plays a dual role in endometrial cancer cells through 
kinase-dependent and kinase-independent mechanisms, respectively, which is in 
accordance with some previous studies in breast (Kumar et al., 2006, Noren et al., 2006, 
Noren and Pasquale, 2007), prostate (Xia et al., 2005b, Rutkowski et al., 2012), and lung 
cancer (Ferguson et al., 2013). Inspired by these findings, we speculate that an imbalance 
between EphB4 and ephrin-B2 levels which could be related to aberrant subcellular 
localisation, and probably also between the levels of EphB4 and other Eph receptors 
renders an autonomous mechanism switch, from kinase-dependent to kinase-independent 
EphB4 signalling pathways increasing the malignant potential in endometrial cancer cells 
(Figure 6.1). 
 
 
Figure 6.1 A proposed model illustrating different effects of EphB4 forward 
signalling in endometrial epithelial cells 
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Normally, EphB4 receptor (red) and ephrin-B2 ligand (green) are located in the different 
membrane microdomains of endometrial epithelial cells where they are coexpressed. 
EphB4/ephrin-B2 binding induces tyrosine phosphorylation of EphB4 and activates its 
kinase activity, which exerts a tumour-suppressor role (left). However, alteration in the 
subcellular location of EphB4 and ephrin-B2 in endometrial cancer cells might result in 
disruption of EphB4/ephrin-B2 interactions causing: 1) both ligand- and kinase-
independent EphB4 signalling which plays a tumor-promoter role; or 2) ligand-dependent 
but kinase-independent EphB4 signalling, of which the biological effects might depend on 
the balance between EphB4 (EB4) and other Eph receptors competitively binding to 
ephrin-B2 (eB2) (right).  
   
In this study, we have demonstrated that restoring the homeostatic balance between 
ephrin-B2 and EphB4 signalling in endometrial cancer cells may offer new therapeutic 
avenue targeting tumours expressing the EphB4 receptor. We found that the soluble 
chimeric ligand ephrin-B2/Fc can promote the activation of kinase-dependent EphB4 
signalling and inhibit the growth of endometrial cancer cells. A previous study showed that 
following 4 hours of stimulation with 3 or 10 μg/ml ephrin-B2/Fc, EphB4 levels in the PC3 
prostate cancer cells began to decline and so did the extent of receptor phosphorylation, 
which was expected due to the endocytosis of ligand-receptor complex and degradation 
(Xia et al., 2005b). It has also been shown that systemic administration of ephrin-B2/Fc at 
low concentrations can inhibit the growth of breast cancer xenografts in nude mice by 
activating the tumour-suppressing EphB4/Abl/Crk pathway (Noren et al., 2006). 
Nonetheless, given the presence of other Eph receptors which might competitively bind to 
ephrin-B2, it is preferable using more selective reagents, such as EphB4 kinase-agonistic 
monoclonal antibodies, to specifically activate anti-oncogenic EphB4 kinase signalling in 
tumour cells and also inhibit the neoangiogenic reverse signalling interplayed with vascular 
ephrin-B2 (Noren and Pasquale, 2007, Boyd et al., 2014). Since EphB4/ephrin-B2 system 
is also essential for the formation and maintenance of normal vasculature, regimes 
developed by this strategy that show a defined tumour-specific effect might pave the way 
for their clinical applications. Moreover, we found that downregulation of EphB4 expression 
with lentiviral shRNAs can potently counteract the oncogenic effects of possible kinase-
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independent EphB4 signalling in endometrial cancer cells. This type of approach using 
antisense oligonucleotides can also inhibit EphB4-dependent tumour angiogenesis (Noren 
and Pasquale, 2007), and thus might be effective in inhibiting the growth of endometrial 
tumours expressing high levels of EphB4. Furthermore, the unique position of the uterus 
that opens into the vaginal makes it feasible to topical administration (such as intrauterine 
douche) of the anti-cancer drugs to increase the efficacy and minimise the systemic side 
effects. Since antibodies and oligonucleotides are small molecules in nature, delivery of 
these putative EphB4-targeted therapies using fabricated nanocarriers might provide a 
promising tool for their clinical applications in endometrial cancer treatment. 
Additionally, identifying new signalling partners and regulators of EphB4/ephrin-B2 system 
might also lead to the development of novel EphB4-targeted therapeutics for endometrial 
cancer. Lack of ER-α in endometrial cancer has been found to be associated with 
epithelial-mesenchymal-transition and reduced patient survival (Wik et al., 2013). The 
EphA2 receptor has been suggested to be associated with low ER and PR expression 
levels in endometrial cancer and poor prognosis (Kamat et al., 2009). Moreover, EphB4 is 
indicated as an upstream regulator of ER-α in human breast cancer cells by modulating 
ER-α transcription (Schmitt et al., 2013). Hence, it is possible that there also exists a 
regulation axis between ER-α and EphB4 in endometrial cancer. However, there is also 
one study reported that no significant correlations could be found between EphB4 
expression and ER expression in the examined endometrial adenocarcinomas (Berclaz et 
al., 2002). The study conducted by Schmitt and colleagues was performed by using a 
kinome-wide small interfering RNA high-throughput screen on multiple breast cancer cell 
lines, and demonstrated that decreased activity of ER-α after EphB4 knockdown is the 
consequence of diminished ER-α mRNA and protein expression, while the study 
performed by Berclaz and colleagues was based on immunohistochemistry analysis on a 
collection of endometrial tumour samples. Thus, results from the former study might be 
more convincing. Nevertheless, the discrepancies in these two studies could also be due 
to the differences in the tissue context between the mammary gland and the endometrium. 
In our study, two ER-α positive endometrial cancer cell lines, Ishikawa and HEC-1B, were 
found to highly express EphB4 proteins. Therefore, further investigation into this potential 
EphB4-ER-α signaling axis could be useful to determine the prognostic value of EphB4 in 
patients received hormonal treatments for this disease. Future studies utilising genomic, 
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proteomic or kinomic analyses are also favourable to identify the interaction networks 
associated with EphB4 function. 
In conclusion, this study provides new insights into the possible roles of the 
EphB4/ephrinB2 system and particularly EphB4 forward signalling in the functional 
regulation of human endometrial cancer. Our results implicate that EphB4 may serve as a 
new therapeutic target in endometrial cancer. Further experiments are necessary to 
answer the raised questions that will hopefully provide a more complete understanding of 
this complex biological system.  
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